ES2586429T3 - Powder filling process - Google Patents
Powder filling process Download PDFInfo
- Publication number
- ES2586429T3 ES2586429T3 ES07759133.7T ES07759133T ES2586429T3 ES 2586429 T3 ES2586429 T3 ES 2586429T3 ES 07759133 T ES07759133 T ES 07759133T ES 2586429 T3 ES2586429 T3 ES 2586429T3
- Authority
- ES
- Spain
- Prior art keywords
- continuous sheet
- roller
- powder
- microdepressions
- speed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 150
- 238000005429 filling process Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 84
- 238000011049 filling Methods 0.000 claims abstract description 68
- 230000008569 process Effects 0.000 claims abstract description 51
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 20
- 230000033001 locomotion Effects 0.000 claims abstract description 18
- 239000000428 dust Substances 0.000 claims description 59
- 238000000926 separation method Methods 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 45
- 238000009825 accumulation Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000005520 cutting process Methods 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims 1
- 239000000463 material Substances 0.000 description 33
- 229940079593 drug Drugs 0.000 description 32
- -1 polyethylene Polymers 0.000 description 32
- 239000010410 layer Substances 0.000 description 27
- 239000002245 particle Substances 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000000969 carrier Substances 0.000 description 13
- 230000035939 shock Effects 0.000 description 9
- 229940088623 biologically active substance Drugs 0.000 description 7
- 229920001684 low density polyethylene Polymers 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000004702 low-density polyethylene Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229940083542 sodium Drugs 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940057282 albuterol sulfate Drugs 0.000 description 3
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 229940112141 dry powder inhaler Drugs 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000005693 optoelectronics Effects 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- VBOQGHUYFLYKOQ-QVRIGTRMSA-N Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 Chemical compound Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 VBOQGHUYFLYKOQ-QVRIGTRMSA-N 0.000 description 2
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960002588 cefradine Drugs 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- 229960002881 clemastine Drugs 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 2
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 2
- 229960001751 fluoxymesterone Drugs 0.000 description 2
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940044170 formate Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000002655 kraft paper Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960000515 nafcillin Drugs 0.000 description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229960000921 testosterone cypionate Drugs 0.000 description 2
- HPFVBGJFAYZEBE-ZLQWOROUSA-N testosterone cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)CC[C@@]21C)C(=O)CCC1CCCC1 HPFVBGJFAYZEBE-ZLQWOROUSA-N 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229960001360 zolmitriptan Drugs 0.000 description 2
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
- ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- ZGSZBVAEVPSPFM-HYTSPMEMSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-HYTSPMEMSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- ZZYHCCDMBJTROG-UHFFFAOYSA-N 2-(2-benzylphenoxy)ethyl-dimethylazanium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O.C[NH+](C)CCOC1=CC=CC=C1CC1=CC=CC=C1 ZZYHCCDMBJTROG-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- YMJMZFPZRVMNCH-FMIVXFBMSA-N 2-[methyl-[(e)-3-phenylprop-2-enyl]amino]-1-phenylpropan-1-ol Chemical compound C=1C=CC=CC=1/C=C/CN(C)C(C)C(O)C1=CC=CC=C1 YMJMZFPZRVMNCH-FMIVXFBMSA-N 0.000 description 1
- RROWJYNAVMZFGT-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid dihydrochloride Chemical compound Cl.Cl.OC(=O)CC(O)(C(O)=O)CC(O)=O RROWJYNAVMZFGT-UHFFFAOYSA-N 0.000 description 1
- NRSJYUSYBNFGAK-UHFFFAOYSA-N 3-bromo-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C=C1Br NRSJYUSYBNFGAK-UHFFFAOYSA-N 0.000 description 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- BPQZYOJIXDMZSX-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BPQZYOJIXDMZSX-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- RKETZVBQTUSNLM-UHFFFAOYSA-N 6-(3-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound BrC1=CC=CC(C2N=C3SCCN3C2)=C1 RKETZVBQTUSNLM-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
- JSXBVMKACNEMKY-UHFFFAOYSA-N 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine;hydron;chloride Chemical compound Cl.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 JSXBVMKACNEMKY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- CEZWYNRAEUWJAN-UHFFFAOYSA-N C1=CC=C2C([Na])CCC2=C1 Chemical compound C1=CC=C2C([Na])CCC2=C1 CEZWYNRAEUWJAN-UHFFFAOYSA-N 0.000 description 1
- GTEBGKZZGCBLNT-RVWNTZLHSA-N CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 Chemical compound CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 GTEBGKZZGCBLNT-RVWNTZLHSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- LIRCDOVJWUGTMW-ZWNOBZJWSA-N Chloramphenicol succinate Chemical compound OC(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 LIRCDOVJWUGTMW-ZWNOBZJWSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- CVBMAZKKCSYWQR-BPJCFPRXSA-N Deserpidine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3 CVBMAZKKCSYWQR-BPJCFPRXSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- ZIIJJOPLRSCQNX-UHFFFAOYSA-N Flurazepam hydrochloride Chemical compound Cl.Cl.N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ZIIJJOPLRSCQNX-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004185 Penicillin G procaine Substances 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 1
- VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- SHUMEODPCRJUBC-UHFFFAOYSA-N Spiraline Natural products C1OC(=O)C(C(C)C)(O)C(C)OC(=O)C(O)C(O)(C(C)C)C(=O)OC2CCN3C2C1=CC3 SHUMEODPCRJUBC-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- SHUMEODPCRJUBC-JLWRCLLRSA-N ac1mj5iv Chemical compound C1OC(=O)[C@@](C(C)C)(O)[C@@H](C)OC(=O)[C@H](O)[C@](O)(C(C)C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 SHUMEODPCRJUBC-JLWRCLLRSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- CZULZVXJPIOKEC-UHFFFAOYSA-N aniline 2,3-dihydroxybutanedioic acid Chemical compound C(=O)(O)C(O)C(O)C(=O)O.NC1=CC=CC=C1 CZULZVXJPIOKEC-UHFFFAOYSA-N 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940021792 ascriptin Drugs 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960003200 azlocillin sodium Drugs 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 description 1
- 229960005412 bacampicillin hydrochloride Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229950003745 benzfetamine Drugs 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960001768 buspirone hydrochloride Drugs 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960001065 cefadroxil monohydrate Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- NAXFZVGOZUWLEP-RFXDPDBWSA-L cefonicid sodium Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS([O-])(=O)=O NAXFZVGOZUWLEP-RFXDPDBWSA-L 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 description 1
- 229960004445 cefotetan disodium Drugs 0.000 description 1
- 229960003016 cefoxitin sodium Drugs 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 229960000534 cefuroxime sodium Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 229940009063 cephapirin sodium Drugs 0.000 description 1
- VGEOUKPOQQEQSX-OALZAMAHSA-M cephapirin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CSC1=CC=NC=C1 VGEOUKPOQQEQSX-OALZAMAHSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960001805 chloramphenicol palmitate Drugs 0.000 description 1
- PXKHGMGELZGJQE-ILBGXUMGSA-N chloramphenicol palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 PXKHGMGELZGJQE-ILBGXUMGSA-N 0.000 description 1
- 229960002579 chloramphenicol sodium succinate Drugs 0.000 description 1
- 229960002810 chlormezanone Drugs 0.000 description 1
- WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229950007046 chlorphentermine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960001750 cinnamedrine Drugs 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- OYSKUZDIHNKWLV-PRUAPSLNSA-N clindamycin palmitate Chemical compound O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 OYSKUZDIHNKWLV-PRUAPSLNSA-N 0.000 description 1
- 229960004714 clindamycin palmitate Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960001054 clorazepate dipotassium Drugs 0.000 description 1
- SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 description 1
- 229960003026 cloxacillin sodium Drugs 0.000 description 1
- 229940108538 colistimethate Drugs 0.000 description 1
- 229960001127 colistin sulfate Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003596 cyproheptadine hydrochloride Drugs 0.000 description 1
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001993 deserpidine Drugs 0.000 description 1
- ISMCNVNDWFIXLM-WCGOZPBSSA-N deserpidine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ISMCNVNDWFIXLM-WCGOZPBSSA-N 0.000 description 1
- XAEWZDYWZHIUCT-UHFFFAOYSA-N desipramine hydrochloride Chemical compound [H+].[Cl-].C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 XAEWZDYWZHIUCT-UHFFFAOYSA-N 0.000 description 1
- 229960003829 desipramine hydrochloride Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229960005372 dexchlorpheniramine maleate Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960001767 dextrothyroxine Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 229960005422 dichloralphenazone Drugs 0.000 description 1
- ATKXDQOHNICLQW-UHFFFAOYSA-N dichloralphenazone Chemical compound OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ATKXDQOHNICLQW-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960002705 dihydrocodeine bitartrate Drugs 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960001342 dinoprost Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- VZFDRQUWHOVFCA-UHFFFAOYSA-L disodium;2-sulfanylbutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S)C([O-])=O VZFDRQUWHOVFCA-UHFFFAOYSA-L 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 229960002861 doxepin hydrochloride Drugs 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000007610 electrostatic coating method Methods 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 229960004121 encainide hydrochloride Drugs 0.000 description 1
- OJIIZIWOLTYOBS-UHFFFAOYSA-N encainide hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 OJIIZIWOLTYOBS-UHFFFAOYSA-N 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960001903 ergotamine tartrate Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003670 flecainide acetate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960001258 fluphenazine hydrochloride Drugs 0.000 description 1
- 229960003628 flurazepam hydrochloride Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229960002764 hydrocodone bitartrate Drugs 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960000375 imipramine pamoate Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960005409 isometheptene mucate Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- RWTWIZDKEIWLKQ-IWWMGODWSA-N levorphan tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 RWTWIZDKEIWLKQ-IWWMGODWSA-N 0.000 description 1
- 229960005157 levorphanol tartrate Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- 229960002018 liothyronine sodium Drugs 0.000 description 1
- SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229940008015 lithium carbonate Drugs 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229960004990 loxapine hydrochloride Drugs 0.000 description 1
- 229960000589 loxapine succinate Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960004992 maprotiline hydrochloride Drugs 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 229940051129 meperidine hydrochloride Drugs 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960005189 methadone hydrochloride Drugs 0.000 description 1
- 229940019826 methicillin sodium Drugs 0.000 description 1
- MGFZNWDWOKASQZ-UMLIZJHQSA-M methicillin sodium Chemical compound [Na+].COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 MGFZNWDWOKASQZ-UMLIZJHQSA-M 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- WSXKZIDINJKWPM-IBGZLQDMSA-N n,6-dimethylhept-5-en-2-amine;(2s,3r,4s,5r)-2,3,4,5-tetrahydroxyhexanedioic acid Chemical compound CNC(C)CCC=C(C)C.CNC(C)CCC=C(C)C.OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O WSXKZIDINJKWPM-IBGZLQDMSA-N 0.000 description 1
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229950006327 napsilate Drugs 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960003994 oxacillin sodium Drugs 0.000 description 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 235000019370 penicillin G procaine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056362 penicillin g procaine Drugs 0.000 description 1
- 229940090663 penicillin v potassium Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229930187379 penicillone Natural products 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- OQGYMIIFOSJQSF-DTOXXUQYSA-N pentazocine hcl Chemical compound Cl.C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 OQGYMIIFOSJQSF-DTOXXUQYSA-N 0.000 description 1
- 229960003809 pentazocine hydrochloride Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229960003396 phenacemide Drugs 0.000 description 1
- 229960004790 phenelzine sulfate Drugs 0.000 description 1
- 229960003006 phenoxybenzamine hydrochloride Drugs 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229960002254 phenyltoloxamine citrate Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 229960005264 piperacillin sodium Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003253 procainamide hydrochloride Drugs 0.000 description 1
- ABTXGJFUQRCPNH-UHFFFAOYSA-N procainamide hydrochloride Chemical compound [H+].[Cl-].CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 ABTXGJFUQRCPNH-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- FJWSMXKFXFFEPV-UHFFFAOYSA-N prop-2-enamide;hydrochloride Chemical compound Cl.NC(=O)C=C FJWSMXKFXFFEPV-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940065347 propoxyphene hydrochloride Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960001509 protriptyline hydrochloride Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229960003141 secobarbital sodium Drugs 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- OGPIIGMUPMPMNT-UHFFFAOYSA-M sodium meclofenamate (anhydrous) Chemical compound [Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl OGPIIGMUPMPMNT-UHFFFAOYSA-M 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- ANMYAHDLKVNJJO-CURYUGHLSA-M sodium;(2r)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;hydrate Chemical compound O.[Na+].IC1=CC(C[C@@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 ANMYAHDLKVNJJO-CURYUGHLSA-M 0.000 description 1
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 description 1
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- XFOHHIYSRDUSCX-UHFFFAOYSA-M sodium;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidin-3-ide-2,4-dione Chemical compound [Na+].C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)[N-]C1=O XFOHHIYSRDUSCX-UHFFFAOYSA-M 0.000 description 1
- AXXJTNXVUHVOJW-UHFFFAOYSA-M sodium;5-pentan-2-yl-5-prop-2-enylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC=C)C(=O)NC(=O)[N-]C1=O AXXJTNXVUHVOJW-UHFFFAOYSA-M 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960004098 thioridazine hydrochloride Drugs 0.000 description 1
- NZFNXWQNBYZDAQ-UHFFFAOYSA-N thioridazine hydrochloride Chemical compound Cl.C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C NZFNXWQNBYZDAQ-UHFFFAOYSA-N 0.000 description 1
- ZBBCUBMBMZNEME-QBGWIPKPSA-L ticarcillin disodium Chemical compound [Na+].[Na+].C=1([C@@H](C([O-])=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)C=CSC=1 ZBBCUBMBMZNEME-QBGWIPKPSA-L 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- BUJAGSGYPOAWEI-UHFFFAOYSA-N tocainide Chemical compound CC(N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229960003797 tranylcypromine sulfate Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 229960002301 trazodone hydrochloride Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 229960002835 trimipramine maleate Drugs 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 229940030300 trolamine salicylate Drugs 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960001572 vancomycin hydrochloride Drugs 0.000 description 1
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229960002647 warfarin sodium Drugs 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Landscapes
- Containers And Plastic Fillers For Packaging (AREA)
Abstract
Un método para llenar una pluralidad de microdepresiones en una superficie principal de una lámina continua teniendo dichas microdepresiones una profundidad de aproximadamente 5 a 500 micras, pero siendo menores que el espesor de la lámina continua, y una abertura en la superficie de la lámina continua de aproximadamente 10 a 500 micras de anchura, con polvo finamente dividido, comprendiendo dicho proceso: suministrar de manera continua la lámina continua a, y a través de, una etapa de llenado de polvo; en la etapa de llenado de polvo, llenar de polvo dichas microdepresiones sobre la superficie de la lámina continua utilizando un rodillo accionado, en donde dicho rodillo está girando alrededor de un eje generalmente transversal a dicha dirección del movimiento de la lámina continua, mientras la velocidad de la superficie del rodillo y la velocidad de la lámina continua son diferentes, y en donde el rodillo y la lámina continua están situados uno con relación al otro, de manera que entre la superficie superior de la lámina continua y la superficie exterior del rodillo hay una separación; y en donde el polvo es suministrado o bien sobre la lámina continua aguas arriba del rodillo de la etapa de llenado de polvo o bien en el rodillo de la etapa de llenado de polvo.A method for filling a plurality of microdepressions on a main surface of a continuous sheet having said microdepressions having a depth of about 5 to 500 microns, but being less than the thickness of the continuous sheet, and an opening in the surface of the continuous sheet of approximately 10 to 500 microns in width, with finely divided powder, said process comprising: continuously supplying the continuous sheet to, and through, a powder filling stage; in the powder filling stage, filling said microdepressions with powder on the surface of the continuous sheet using a driven roller, wherein said roller is rotating about an axis generally transverse to said direction of continuous sheet movement, while the speed of the surface of the roller and the speed of the continuous sheet are different, and where the roller and the continuous sheet are located relative to each other, so that between the upper surface of the continuous sheet and the outer surface of the roller there is a seperation; and where the powder is supplied either on the continuous sheet upstream of the roller of the powder filling stage or on the roller of the powder filling stage.
Description
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
DESCRIPCIONDESCRIPTION
Proceso de llenado de polvo CampoField Powder Filling Process
La presente invencion se refiere a un proceso para el llenado de polvo finamente dividido en una pluralidad de microdepresiones en la superficie de una lamina continua flexible, asf como a un metodo de fabricacion de un portador alargado con microdepresiones que contienen polvo finamente dividido. La lamina continua rellena y o el portador alargado se pueden utilizar de manera conveniente en la administracion de sustancias biologicamente activas, en participar medicamentos, mediante inhalacion.The present invention relates to a process for filling finely divided powder into a plurality of microdepressions on the surface of a flexible continuous sheet, as well as to a method of manufacturing an elongated carrier with microdepressions containing finely divided powder. The filled continuous sheet and or the elongated carrier can be conveniently used in the administration of biologically active substances, in participating medications, by inhalation.
AntecedentesBackground
El asma y otras enfermedades respiratorias han sido tratados durante largo tiempo mediante la inhalacion de un medicamento apropiado. Durante muchos anos, las dos posibilidades de tratamiento mas ampliamente utilizadas y mas convenientes han sido la inhalacion de un medicamente a partir de una solucion o suspension de farmaco en un inhalador de dosis medida presurizado (pMDI), o la inhalacion de un farmaco en polvo, generalmente mezclado con un excipiente, a partir de un inhalador de polvo seco (DPI). Tras la fuerte preocupacion acerca de la relacion entre la reduccion de la capa de ozono y las emisiones de clorofluorocarbono (CFC), el uso de esos materiales en inhaladores a presion ha ido cayendo en desuso aumentando en interes por los sistemas DPI.Asthma and other respiratory diseases have been treated for a long time by inhaling an appropriate medication. For many years, the two most widely used and most convenient treatment possibilities have been the inhalation of a medication from a drug solution or suspension in a pressurized metered dose inhaler (pMDI), or the inhalation of a powdered drug , usually mixed with an excipient, from a dry powder inhaler (DPI). After the strong concern about the relationship between the reduction of the ozone layer and the emissions of chlorofluorocarbon (CFC), the use of these materials in pressure inhalers has fallen into disuse, increasing interest in IPR systems.
La mayona de los DPIs utilizan o bien depositos de polvo a granel o bien dosis medidas previamente individuales. Sin embargo, existen problemas asociados con la medicion precisa de una pequena cantidad medida (por ejemplo 500 miligramos o menos) de polvo tanto a partir del deposito a granel dentro de un inhalador como dentro de una capsula o ampolla. Con muchos farmacos, por ejemplo farmacos potentes, esto introduce la necesidad de anadir excipientes, tales como polvo de lactosa, para aumentar significativamente la cantidad de polvo que va ser medida. Tales excipientes son, sin embargo, generalmente indeseables ya que pueden representar problemas de desaglomeracion de polvo posteriores y pueden producir sequedad y otros efectos no deseados en la boca del paciente.The majority of the DPIs use either bulk powder deposits or previously individual measured doses. However, there are problems associated with the precise measurement of a small measured amount (for example 500 milligrams or less) of powder both from the bulk deposit within an inhaler and within a capsule or vial. With many drugs, for example potent drugs, this introduces the need to add excipients, such as lactose powder, to significantly increase the amount of powder to be measured. Such excipients are, however, generally undesirable since they can represent subsequent dust breakdown problems and can cause dryness and other unwanted effects in the patient's mouth.
Los inhaladores de polvo seco en los que son dispensadas dosis predeterminadas de medicamento a partir de un material laminar que incluye microdepresiones discretas (que tienen una profundidad de aproximadamente 5 a 500 micras y una abertura en la superficie del material laminar de aproximadamente 10 a 500 micras de anchura) rellenos con medicamento, se describen en las patentes de Estados Unidos 5.408.994, 5.437.271, 5.469.843, 5.482.032 y 5.655.523.Dry powder inhalers in which predetermined doses of medication are dispensed from a sheet material that includes discrete microdepressions (having a depth of about 5 to 500 microns and a surface opening of the sheet material of about 10 to 500 microns wide) filled with medication, are described in US Patents 5,408,994, 5,437,271, 5,469,843, 5,482,032 and 5,655,523.
Se conocen diversos metodos para el revestimiento de polvo sobre sustratos. Algunos tfpicos en consideracion para utilizar en aplicaciones de administracion de farmacos son los metodos de revestimiento electrostaticos descritos en las patentes de Estados Unidos 4.197.289, 5.699.649, 5.960.609, 6.146.685, 6.319.541 y 6.652.903 y la solicitud de patente de Estados Unidos US2002/0085977. Tales metodos tienden a ser complejos, lentos y diffciles de controlar.Various methods for powder coating on substrates are known. Some typical in consideration for use in drug administration applications are the electrostatic coating methods described in US Patents 4,197,289, 5,699,649, 5,960,609, 6,146,685, 6,319,541 and 6,652,903 and the United States patent application US2002 / 0085977. Such methods tend to be complex, slow and difficult to control.
Otros metodos para el revestimiento de polvos en sustratos de lamina continua en movimiento incluyen metodos de lecho fluidificado, por ejemplo como se ha descrito en las patentes de Estados Unidos 4.088.093 y 6.037.019, metodos de rociado, (por ejemplo las patentes de Estados Unidos 4.288.521 y 5.897.746), metodos de succion (por ejemplo la patente de Estados Unidos 4.313.972) metodos magneticos (por ejemplo la patente de Estados Unidos 4.470.350), y metodos de espolvoreo (por ejemplo las patentes de Estados Unidos 4.209.553 y 5.415.717). Un metodo para depositar partfculas suspendidas en un sustrato para utilizar en dispositivos de inhalacion, que implica la evaporacion del agente en suspension, se describe en la patente de Estados Unidos 5.503.869. Sin embargo, ninguno de estos distintos metodos se adapta bien a la medicion precisa de polvos farmaceuticos en microdepresiones sobre una superficie de una lamina continua.Other methods for coating powders on moving continuous film substrates include fluidized bed methods, for example as described in US Patents 4,088,093 and 6,037,019, spray methods, (e.g. United States 4,288,521 and 5,897,746), suction methods (for example US Patent 4,313,972) magnetic methods (for example US Patent 4,470,350), and sprinkling methods (for example patents United States 4,209,553 and 5,415,717). A method of depositing suspended particles on a substrate for use in inhalation devices, which involves evaporation of the suspended agent, is described in US Patent 5,503,869. However, none of these different methods is well suited to the precise measurement of pharmaceutical powders in microdepressions on a continuous sheet surface.
La solicitud de patente WO 95/21768 describe un proceso para el llenado de cavidades de ampollas con polvo mientras estan montadas en una lamina continua. Se proporciona un sistema oscilante y giratorio para romper los agregados en dosis de polvo de 0,1 a 10 mg. Tales masas grandes de polvos son muchas veces mayores que las cantidades pequenas de polvo que los inhaladores basados en cinta con microdepresiones descritos en las patentes anteriormente mencionadas estan destinados a administrar.Patent application WO 95/21768 describes a process for filling blister cavities with powder while mounted on a continuous sheet. An oscillating and rotating system is provided to break the aggregates in powder doses of 0.1 to 10 mg. Such large masses of powders are many times greater than the small amounts of powder that the tape-based inhalers with microdepressions described in the aforementioned patents are intended to be administered.
El documento US 5.192.548 describe un metodo de revestimiento de un farmaco micronizado en un lazo cerrado de un material laminar que incluye microdepresiones en su lado superior, en el que el farmaco micronizado es suministrado sobre el material laminar, rodillos ayudan en la distribucion del farmacos micronizado sobre la superficie del material laminar y listones curvados funcionan para untar el farmaco micronizado sobre la superficie del material laminar. Un rodillo se muestra con una parte aplanada destinada a ayudar a evitar que el farmaco se acumule detras de el.US 5,192,548 describes a method of coating a micronized drug in a closed loop of a sheet material that includes microdepressions on its upper side, in which the micronized drug is supplied on the sheet material, rollers help in the distribution of the Micronized drugs on the surface of the sheet material and curved slats work to spread the micronized drug on the surface of the sheet material. A roller is shown with a flattened part intended to help prevent the drug from accumulating behind it.
El documento WO 95/21768 se refiere a un dispositivo para llenar con elevada precision un medicamento en polvo finamente dividido que tiene un tamano de partfcula menor que 10 pm cavidades que tienen un tamano correspondiente al volumen del polvo que va a ser llenado, en donde dicho dispositivo comprende medios deWO 95/21768 refers to a device for filling with high precision a finely divided powder medicine having a particle size smaller than 10 pm cavities that have a size corresponding to the volume of the powder to be filled, where said device comprises means of
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
oscilacion y rotacion para romper los agregados formados en el medicamento en polvo finamente dividido y para llenarlo y compactarlo en dichas cavidades.oscillation and rotation to break the aggregates formed in the finely divided powder medicine and to fill and compact it in said cavities.
El documento WO 92/19198 describe una configuracion para depositar partfculas en una lamina continua en movimiento. La configuracion incluye un dispensador de partfculas y una cinta perforada que se mueve sobre la lamina continua de material. El dispensador de partfculas esta destinado a dispensar las partfculas de forma continua en un flujo uniforme y ancho cuya anchura es igual o algo mayor que la anchura del patron de orificios de la cinta y la cinta esta separada una distancia de la lamina continua de material que es al menos lo suficientemente grande para que las partfculas depositadas sobre la lamina continua de material queden alojadas entre la cinta y la lamina continua.WO 92/19198 describes a configuration for depositing particles in a continuous sheet in motion. The configuration includes a particle dispenser and a perforated tape that moves on the continuous sheet of material. The particle dispenser is intended to dispense the particles continuously in a uniform and wide flow whose width is equal to or greater than the width of the orifice pattern of the tape and the tape is separated a distance from the continuous sheet of material that It is at least large enough for the particles deposited on the continuous sheet of material to be housed between the tape and the continuous sheet.
Sumario de la invencionSummary of the invention
Aun existe la necesidad de proporcionar procesos para llenar de forma precisa y uniforme microdepresiones con polvo finamente dividido (en particular, sustancias biologicamente activas, tales como medicamentos) y/o proporcionar procesos para la fabricacion de portadores alargados que tienen microdepresiones llenas de forma sustancialmente precisa y uniforme con dichos polvos finamente divididos, en particular operando tales procesos de forma continua y/o adecuada para el uso a escala industrial.There is still a need to provide processes for accurately and uniformly filling microdepressions with finely divided powder (in particular, biologically active substances, such as medicaments) and / or providing processes for the manufacture of elongated carriers that have substantially precisely filled microdepressions. and uniform with said finely divided powders, in particular operating such processes continuously and / or suitable for use on an industrial scale.
De acuerdo un aspecto de la presente invencion se proporciona un metodo para llenar una pluralidad de microdepresiones, en una superficie principal de una lamina continua, con polvo finamente dividido en el que la lamina continua es suministrada de forma continua y a traves de una etapa de llenado de polvo que contiene un rodillo accionado. En la etapa de llenado de polvo, el polvo que es suministrado o bien sobre la lamina continua aguas arriba del rodillo o bien en el rodillo de la etapa de llenado de polvo, es introducido en las microdepresiones de la lamina continua utilizando el rodillo accionado, en donde dicho rodillo es giratorio alrededor de un eje generalmente transversal a la direccion del movimiento de la lamina continua, mientras que la velocidad de la superficie del rodillo y la velocidad de la lamina continua son diferentes y en donde el rodillo y la lamina continua estan situados uno con relacion al otro, de manera que entre la superficie superior de la lamina continua y la superficie exterior del rodillo existe una separacion.According to one aspect of the present invention there is provided a method for filling a plurality of microdepressions, on a main surface of a continuous sheet, with finely divided powder in which the continuous sheet is supplied continuously and through a filling stage. of powder containing a driven roller. In the powder filling stage, the powder that is supplied either on the continuous sheet upstream of the roller or on the roller of the powder filling stage, is introduced into the microdepressions of the continuous sheet using the driven roller, wherein said roller is rotatable about an axis generally transverse to the direction of movement of the continuous sheet, while the speed of the surface of the roller and the speed of the continuous sheet are different and where the roller and the continuous sheet are located in relation to each other, so that there is a gap between the upper surface of the continuous sheet and the outer surface of the roller.
Otro aspecto de la presente invencion es la provision de un metodo de fabricacion de un portador alargado de microdepresiones que contienen polvo finamente dividido, comprendiendo el proceso la etapa de llenar una pluralidad de microdepresiones en una superficie principal de una lamina continua como se ha descrito anteriormente y que comprende ademas la etapa de retirar de la superficie superior de la lamina continua el exceso de polvo no depositado dentro de la microdepresiones y que permanece en las areas de la superficie entre las depresiones. De manera adicional, si se desea, en la lamina continua con las microdepresiones llenas se pueden formar hendiduras o se puede cortar a anchuras predeterminadas y/o longitudes predeterminadas.Another aspect of the present invention is the provision of a method of manufacturing an elongated carrier of microdepressions containing finely divided powder, the process comprising the step of filling a plurality of microdepressions on a main surface of a continuous sheet as described above. and which also includes the step of removing excess dust not deposited within the microdepressions from the upper surface of the sheet and remaining in the surface areas between the depressions. Additionally, if desired, grooves can be formed in the continuous sheet with full microdepressions or cut to predetermined widths and / or predetermined lengths.
Sorprendentemente, aplicando diferentes velocidades a la superficie del rodillo accionado y a la lamina continua, y colocando el rodillo y la lamina continua uno con relacion al otro para proporcionar una separacion entre la superficie exterior del rodillo y la superficie superior de la lamina continua, durante el funcionamiento del proceso de suministro de polvo y llenado de la superficie exterior del rodillo se forma una cubierta sustancial de polvo de forma visualmente uniforme (por ejemplo, visualmente uniforme en lisura y espesor) y la capa continua, que permite la precision deseable y el llenado uniforme de la microdepresiones. La formacion de una cubierta estable, sustancial de polvo sobre el rodillo es deseablemente facilitada a traves de la aplicacion de una anchura de separacion de 1,25 mm o menor. La aplicacion de una anchura de separacion de 0,2 mm o mayor es deseable para un proceso de llenado estable y liso. Los procesos estables de llenado uniforme de polvo en las depresiones de la lamina continua en movimiento encontrados para una anchura de separacion fija, sin embargo un elemento de flexibilidad en el posicionamiento del rodillo y la lamina continua se ha encontrado que es ventajoso para que la separacion sea variable en anchura. Por ejemplo, para facilitar la prevencion de la formacion de presiones elevadas en el rodillo, debido a la acumulacion de polvo en la separacion, el posicionamiento del rodillo y la lamina continua pueden estar dispuestos de manera que la separacion este cargada hacia una anchura minima predeterminada, por ejemplo, a traves del uso de muelles, pero permitiendo al mismo tiempo algo de variabilidad en la anchura de separacion, por ejemplo, movimiento hacia una anchura de separacion mayor.Surprisingly, by applying different speeds to the surface of the driven roller and the continuous sheet, and placing the roller and the continuous sheet relative to each other to provide a separation between the outer surface of the roller and the upper surface of the continuous sheet, during the operation of the powder supply process and filling of the outer surface of the roller a substantial dust cover is formed visually uniform (eg visually uniform in smoothness and thickness) and the continuous layer, which allows for desirable precision and filling uniform microdepressions. The formation of a stable, substantial dust cover on the roller is desirably facilitated through the application of a separation width of 1.25 mm or less. The application of a separation width of 0.2 mm or greater is desirable for a stable and smooth filling process. Stable processes of uniform powder filling in the depressions of the continuous moving sheet found for a fixed separation width, however an element of flexibility in the positioning of the roller and the continuous sheet has been found to be advantageous for the separation be variable in width. For example, to facilitate the prevention of the formation of high pressures in the roller, due to the accumulation of dust in the separation, the positioning of the roller and the continuous sheet may be arranged so that the separation is loaded to a predetermined minimum width , for example, through the use of springs, but at the same time allowing some variability in the separation width, for example, movement towards a greater separation width.
La formacion de una cubierta estable, sustancial de polvo sobre el rodillo tambien es deseable, facilitada por la rotacion del rodillo en la misma direccion que el movimiento de la lamina continua. Ademas, la provision de una velocidad de superficie de rodillo que es mayor que la velocidad se ha encontrado util para mantener una cubierta de polvo estable sobre el rodillo durante el llenado. Una velocidad de superficie para el rodillo que sea 1,1 o mas veces mayor que la velocidad de lamina continua se ha encontrado particularmente util.The formation of a stable, substantial dust cover on the roller is also desirable, facilitated by the rotation of the roller in the same direction as the movement of the continuous sheet. In addition, the provision of a roller surface speed that is greater than the speed has been found useful in maintaining a stable dust cover on the roller during filling. A surface speed for the roller that is 1.1 or more times greater than the continuous sheet speed has been found particularly useful.
Incluso para llenar de forma mas facil, asf como para conseguir la fiabilidad y estabilidad del proceso mejorada, se ha encontrado deseable suministrar la lamina continua al rodillo generalmente a lo largo de un primer plano y desde el rodillo a lo largo de un segundo plano, de manera que en el rodillo, la lamina continua atraviesa un quiebro, en donde el primer plano y el segundo plano definen un angulo de menos de 180° hacia el rodillo (referido en lo que sigue como “angulo de contacto”). Aunque no se desea que se lfmite a una teona particular, se cree que la provision de tal angulo de contacto permite una envuelta parcial alrededor de la lamina continua en el rodillo proporcionandoEven to fill more easily, as well as to achieve improved process reliability and stability, it has been found desirable to supply the continuous sheet to the roller generally along a foreground and from the roller along a background, so that in the roller, the continuous sheet goes through a break, where the first plane and the second plane define an angle of less than 180 ° towards the roller (referred to in the following as "contact angle"). Although it is not desired that it be limited to a particular theone, it is believed that the provision of such a contact angle allows a partial wrap around the continuous sheet in the roller providing
un componente de fuerza directamente normal al revestimiento de polvo sobre el rodillo.a force component directly normal to the powder coating on the roller.
Debido a la deseable precision y uniformidad en los procesos de acuerdo con la invencion, estos procesos son particularmente adecuados para llenar laminas continuas y/o fabricar portadores alargados con una sustancia biologicamente activa. Ademas, las laminas continuas llenas y/o los portadores alargados como estan dispuestos 5 por los procesos descritos aqrn, que incluyen cantidades pequenas y medidas bien controladas de una sustancia biologicamente activa, se pueden utilizar de manera ventajosa como tales o como una parte de los sistemas de suministro para la administracion de tales polvos formados por una sustancia o sustancias biologicamente activas.Due to the desirable precision and uniformity in the processes according to the invention, these processes are particularly suitable for filling continuous sheets and / or manufacturing elongated carriers with a biologically active substance. In addition, continuous filled sheets and / or elongated carriers as provided by the processes described herein, which include small quantities and well-controlled measures of a biologically active substance, can be advantageously used as such or as a part of the supply systems for the administration of such powders formed by a biologically active substance or substances.
De acuerdo con una primera realizacion de la presente invencion, se proporciona un metodo para llenar una pluralidad de microdepresiones en una superficie principal de una lamina continua, teniendo dichas 10 microdepresiones una profundidad de aproximadamente 5 a 500 micras, pero siendo menor que el espesor de la lamina continua y una abertura en la superficie de la lamina continua de aproximadamente 10 a 500 micrones de anchura, con un polvo finamente dividido, comprendiendo dicho proceso: llenar de manera continua la lamina continua a traves de una etapa de llenado de polvo; en la etapa de llenado de polvo, introducir el polvo en las microdepresiones sobre la superficie de la lamina continua utilizando un rodillo accionado, en donde dicho rodillo 15 accionad esta girando alrededor de un eje generalmente transversal a dicha direccion de movimiento, mientras la velocidad de superficie del rodillo y la velocidad de la lamina continua son diferentes y en donde el rodillo y la lamina continua estan colocados uno con relacion al otro, de manera que entre la superficie superior de la lamina continua y la superficie exterior del rodillo existe una separacion; y en donde el polvo es suministrado, o bien sobre la lamina continua aguas arriba del rodillo de la etapa de llenado de polvo, o bien en el rodillo de la etapa de llenado de polvo.According to a first embodiment of the present invention, a method is provided for filling a plurality of microdepressions on a main surface of a continuous sheet, said 10 microdepressions having a depth of about 5 to 500 microns, but being less than the thickness of the continuous sheet and an opening in the surface of the continuous sheet approximately 10 to 500 microns wide, with a finely divided powder, said process comprising: continuously filling the continuous sheet through a powder filling stage; in the powder filling stage, introducing the powder into the microdepressions on the surface of the continuous sheet using a driven roller, wherein said driven roller 15 is rotating around an axis generally transverse to said direction of movement, while the speed of The surface of the roller and the speed of the continuous sheet are different and where the roller and the continuous sheet are positioned relative to each other, such that there is a gap between the upper surface of the continuous sheet and the outer surface of the roller; and where the powder is supplied, either on the continuous sheet upstream of the roller of the powder filling stage, or on the roller of the powder filling stage.
20 De acuerdo con una realizacion mas de la presente invencion, se proporciona un metodo de fabricacion de un portador alargado con microdepresiones que contienen polvo finamente dividido, comprendiendo dicho proceso: proporcionar una lamina continua que comprende una pluralidad de microdepresiones en una superficie principal de la lamina continua, teniendo dichas microdepresiones una profundidad de aproximadamente 5 a 500 micras pero siendo menor que el espesor de la lamina continua y una abertura en la superficie de la lamina continua de 25 aproximadamente 10 a 500 micras de anchura, suministrar de forma continua la lamina continua a, y a traves de, una etapa de llenado de polvo a la etapa de llenado de polvo, depositar en polvo dentro de dichas microdepresiones sobre la superficie de la lamina continua utilizando un rodillo accionado, en donde dicho rodillo esta girando alrededor de un eje generalmente transversal a dicha direccion del movimiento de la lamina continua, mientras la velocidad de superficie del rodillo y la velocidad de lamina continua son diferentes y en donde el rodillo y la lamina 30 continua estan situados uno con relacion al otro, de manera que entre la superficie superior de la lamina a continua y la superficie exterior del rodillo existe una separacion; retirar de dicha superficie de la lamina continua el exceso de polvo que ha llenado las microdepresiones y que permanece en las area de la superficie entre las depresiones; y opcionalmente formar hendiduras y/o cortar la lamina continua a unas anchuras y/o longitudes predeterminadas; y en donde el polvo es suministrado sobre la lamina continua aguas arriba de rodillo de la etapa de llenado de polvo o 35 al rodillo de la etapa de llenado de polvo.According to a further embodiment of the present invention, there is provided a method of manufacturing an elongated carrier with microdepressions containing finely divided powder, said process comprising: providing a continuous laminate comprising a plurality of microdepressions on a main surface of the continuous sheet, said microdepressions having a depth of about 5 to 500 microns but being less than the thickness of the continuous sheet and an opening in the surface of the continuous sheet of about 10 to 500 microns in width, continuously supplying the sheet continues to, and through, a powder filling stage to the powder filling stage, depositing powder within said microdepressions on the surface of the continuous sheet using a driven roller, wherein said roller is rotating about an axis generally transverse to said direction of continuous sheet movement, while the v The surface quality of the roller and the speed of the continuous sheet are different and where the roller and the continuous sheet 30 are located relative to each other, so that between the upper surface of the continuous sheet and the outer surface of the roller there is a seperation; removing from said surface of the sheet the excess dust that has filled the microdepressions and that remains in the surface areas between the depressions continues; and optionally forming slits and / or cutting the continuous sheet to predetermined widths and / or lengths; and wherein the powder is supplied on the continuous sheet upstream of the roller of the powder filling stage or 35 to the roller of the powder filling stage.
Las reivindicaciones dependientes definen realizaciones adicionales de la invencionThe dependent claims define further embodiments of the invention.
Breve descripcion de los dibujosBrief description of the drawings
La invencion se describira a continuacion con mas detalle con referencia a los dibujos adjuntos en los que:The invention will be described in more detail below with reference to the accompanying drawings in which:
La Figura 1 representa una ilustracion esquematica de un dispositivo a modo de ejemplo para llenar con polvo 40 finamente dividido microdepresiones en una superficie principal de una lamina continua utilizando un proceso a modo de ejemplo, de acuerdo con la invencion.Figure 1 represents a schematic illustration of an exemplary device for filling microdepressions with a finely divided powder on a main surface of a continuous sheet using an exemplary process, in accordance with the invention.
La Figura 2 representa una ilustracion esquematica del suministro de la lamina continua a, y desde, el rodillo ilustrado en la Figura 1.Figure 2 represents a schematic illustration of the continuous sheet supply to, and from, the roller illustrated in Figure 1.
Descripcion detalladaDetailed description
45 Se entiende que la presente invencion cubre todas las combinaciones de aspectos particulares, adecuados, deseables, favorables, ventajosos y preferidos de la invencion descrita aquf45 It is understood that the present invention covers all combinations of particular, suitable, desirable, favorable, advantageous and preferred aspects of the invention described herein.
Haciendo referencia a la Figura 1 que proporciona una ilustracion esquematica de un dispositivo a modo de ejemplo (1) para llenar con polvo finamente dividido microdepresiones de una lamina continua utilizando un proceso a modo de ejemplo de acuerdo con la invencion, la lamina continua (8) es generalmente suministrada de forma continua a, y 50 a traves de, una etapa de llenado de polvo (15). La lamina continua (8) puede ser suministrada desde un rodillo (no mostrado).Referring to Figure 1, which provides a schematic illustration of an exemplary device (1) for filling microdepressions of a continuous sheet with finely divided powder using an exemplary process according to the invention, the continuous sheet (8). ) is generally supplied continuously to, and 50 through, a powder filling stage (15). The continuous sheet (8) can be supplied from a roller (not shown).
Las laminas continuas para utilizar en el proceso descrito aqrn, comprenden una pluralidad de microdepresiones en una superficie principal de la lamina continua. Las microdepresiones pueden ser conos truncados adecuadamente, pero alternativamente pueden tener cualquier configuracion adecuada para contener polvo finamente dividido, 55 incluyendo piramides truncadas, semiesferas parciales, y tetraedros u otras configuraciones geometricas asf como configuraciones no geometricas. Las depresiones preferidas tienen un angulo de pared lateral de 15°-20° con laThe continuous sheets for use in the process described herein comprise a plurality of microdepressions on a main surface of the continuous sheet. The microdepressions may be suitably truncated cones, but alternatively they may have any suitable configuration to contain finely divided dust, including truncated pyramids, partial hemispheres, and tetrahedra or other geometric configurations as well as non-geometric configurations. Preferred depressions have a lateral wall angle of 15 ° -20 ° with the
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
vertical cuando la superficie principal es horizontal. La pluralidad de depresiones puede estar dispuesta en una configuracion irregular, o alternativamente la configuracion de depresiones puede adoptar cualquier forma o patron y no necesita ser regular (es decir, la disposicion puede ser de aspecto irregular). De manera deseable, las microdepresiones son discretas.vertical when the main surface is horizontal. The plurality of depressions can be arranged in an irregular configuration, or alternatively the configuration of depressions can take any form or pattern and does not need to be regular (that is, the arrangement can be irregular in appearance). Desirably, the microdepressions are discrete.
Las depresiones generalmente tienen una profundidad de aproximadamente 5 a 500 micras y una abertura en la superficie de la lamina continua de aproximadamente 10 a 500 micras de anchura. La depresiones tienen una profundidad menor que el espesor de la lamina continua, de manera que las depresiones no forman poros que se extiendan a traves de todo el espesor de la lamina continua. En el caso de depresiones discretas que tienen aberturas circulares tales como conos truncados o semiesferas parciales, por ejemplo, la achura expuesta anteriormente es, de hecho, el diametro de la abertura circular. Las depresiones preferidas tienen una profundidad de aproximadamente 5 a 150 micras y una abertura (por ejemplo, diametro en el caso de conos truncados discretos o semiesferas parciales o similares) en la superficie del material laminar de aproximadamente 50 a 200 micras. Las depresiones pueden estar separadas de manera adecuada en un intervalo de aproximadamente 20 a 2000 micras, mas adecuadamente en un intervalo de aproximadamente 300 a 2000 micras. Las depresiones pueden ser adecuadamente en un numero de entre aproximadamente 25 y 1000 por cm2 de lamina continua. El volumen de cada depresion y la separacion o numero de depresiones dependera de la aplicacion particular deseada de la lamina continua llena resultante y/o el portador alargado en el caso de sustancias biologicamente activas (por ejemplo, medicamentos), la potencia de la sustancia particular y el area del material laminar destinada a representar una unica dosis de la sustancia. Tfpicamente es deseable que el material de lamina continua tenga un volumen de depresion sustancialmente uniforme por unidad de area cuando se considera en una escala del area de una unica dosis u otra unidad funcional.The depressions generally have a depth of about 5 to 500 microns and an opening in the surface of the continuous sheet of about 10 to 500 microns in width. The depressions have a depth less than the thickness of the continuous sheet, so that the depressions do not form pores that extend across the entire thickness of the continuous sheet. In the case of discrete depressions having circular openings such as truncated cones or partial hemispheres, for example, the above-mentioned achura is, in fact, the diameter of the circular opening. Preferred depressions have a depth of about 5 to 150 microns and an opening (for example, diameter in the case of discrete truncated cones or partial or similar hemispheres) on the surface of the sheet material of about 50 to 200 microns. Depressions may be adequately separated in a range of about 20 to 2000 microns, more suitably in a range of about 300 to 2000 microns. Depressions can be suitably in a number between about 25 and 1000 per cm2 of continuous sheet. The volume of each depression and the separation or number of depressions will depend on the particular desired application of the resulting continuous full sheet and / or the elongated carrier in the case of biologically active substances (e.g., medications), the potency of the particular substance and the area of the sheet material intended to represent a single dose of the substance. Typically it is desirable that the continuous sheet material have a substantially uniform volume of depression per unit area when considered on a scale of the area of a single dose or other functional unit.
Las depresiones pueden estar formadas en un material de lamina continua mediante cualquier tecnica adecuada tal como microimpresion utilizando una placa de aleacion de magnesio con un patron fotolitografico u otra placa micromecanizada. Otras tecnicas convencionales que se pueden utilizar son la generacion optica de imagenes o la generacion de imagenes por laser.The depressions can be formed in a continuous sheet material by any suitable technique such as microprinting using a magnesium alloy plate with a photolithographic pattern or another micromachined plate. Other conventional techniques that can be used are the optical generation of images or the generation of images by laser.
Las laminas continuas para utilizar en los procesos descritos aqu son generalmente flexibles. La lamina continua puede ser un material de capa (unica) o un estratificado que incluye una capa pegada (por ejemplo estratificada, unida o extruida) sobre una capa de soporte. Las capas de soporte pueden estar formadas por papel, ser no tricotadas, tricotadas, pelfculas de malla o polimericas, tales como pelfculas de poliester. De manera adecuada, la lamina continua, como un unico material o como una capa del mismo fijada a una capa de soporte, puede comprender una material polimerico (tal como polietileno, polipropileno, poliester, politetrafluoretileno o mezclas de los mismos, en particular polietileno o polipropileno). Para el llenado con polvos que son sensibles a la humedad, puede ser deseable incorporar un material secante. Tambien, sales inorganicas o materiales conductores bien dispersados se pueden incorporar tambien en el material de lamina continua para disminuir cualquier carga estatica que se puede acumular en la lamina continua.Continuous sheets for use in the processes described herein are generally flexible. The continuous sheet can be a (single) layer material or a laminate that includes a bonded layer (for example laminated, bonded or extruded) on a support layer. The support layers may be formed by paper, be non-knitted, knitted, mesh or polymeric films, such as polyester films. Suitably, the continuous sheet, as a single material or as a layer thereof fixed to a support layer, may comprise a polymeric material (such as polyethylene, polypropylene, polyester, polytetrafluoroethylene or mixtures thereof, in particular polyethylene or Polypropylene). For filling with powders that are sensitive to moisture, it may be desirable to incorporate a drying material. Also, inorganic salts or well dispersed conductive materials can also be incorporated into the continuous sheet material to decrease any static load that can accumulate in the continuous sheet.
Generalmente, las laminas continuas formadas, o bien por un material unico o bien como un estratificado, tienen una espesor de al menos 25 micras. Las laminas continuas que tienen un espesor de al menos 75 micras son mas adecuadas y un espesor de al menos 100 micas es lo mas adecuado. Las laminas continuas que tienen un espesor de como mucho 1000 miras son generalmente adecuadas, mientras que las laminas continuas que tienen un espesor de como mucho 750 micras son mas adecuadas, como mucho 500 micras incluso mas adecuadas y como mucho 250 micras lo mas adecuado. Un ejemplo de material adecuado para una lamina continua de material unico incluye polipropileno, debido a que el polipropileno presenta suficiente integridad y durabilidad sin la inclusion de una capa de soporte. Un ejemplo de una lamina continua estratificada adecuada incluye papel de kraft revestido de polietileno.Generally, the continuous sheets formed, either by a single material or as a laminate, have a thickness of at least 25 microns. Continuous sheets having a thickness of at least 75 microns are more suitable and a thickness of at least 100 micas is most suitable. Continuous sheets having a thickness of at most 1000 sights are generally adequate, while continuous sheets having a thickness of at most 750 microns are more suitable, at most 500 microns even more suitable and at most 250 microns as appropriate. An example of suitable material for a continuous sheet of single material includes polypropylene, because the polypropylene has sufficient integrity and durability without the inclusion of a support layer. An example of a suitable laminated continuous sheet includes kraft paper coated with polyethylene.
Volviendo a la Figura 1, la lamina continua (8) puede ser suministrada a una etapa de llenado de polvo (50) en donde el polvo finamente dividido (4) es suministrado sobre la superficie superior de la lamina continua, comprendiendo dicha superficie una pluralidad de microdepresiones (no mostradas). El movimiento de la lamina continua en la direccion general indicada por la flecha (10) entonces hace que el polvo sobre la lamina continua viaje con la lamina continua a la etapa de llenado de polvo (15) que incluye un rodillo accionado (12).Returning to Figure 1, the continuous sheet (8) can be supplied to a powder filling stage (50) where the finely divided powder (4) is supplied on the upper surface of the continuous sheet, said surface comprising a plurality of microdepressions (not shown). The movement of the sheet continues in the general direction indicated by the arrow (10) then causes the powder on the sheet to continue traveling with the sheet continuing to the powder filling stage (15) which includes a driven roller (12).
La disposicion de suministro de polvo puede ser de cualquier forma adecuada para suministrar polvo, o bien directamente al rodillo de la etapa de llenado de polvo, o bien sobre la superficie de la lamina continua aguas arriba del rodillo de la etapa de llenado de polvo. La Figura 1 muestra una representacion a modo de ejemplo de este ultimo tipo de suministro de polvo.The powder delivery arrangement can be in any way suitable for delivering powder, either directly to the roller of the powder filling stage, or on the surface of the continuous sheet upstream of the roller of the powder filling stage. Figure 1 shows an exemplary representation of this last type of powder supply.
En un segundo tipo de suministro de polvo, el polvo puede ser proporcionada, por ejemplo, sobre la superficie superior de la lamina continua aguas arriba de un “nip”, o separacion del rodillo, en el lado aguas arriba del rodillo (por ejemplo, cerca de la separacion debajo del rodillo de la etapa de llenado de polvo). Permitiendo que un exceso de polvo se acumule como una elevacion de choque en la separacion del rodillo, la elevacion de choque puede actuar como un deposito, y asegurar la continuidad y la uniformidad del proceso de aplicacion de polvo. De manera conveniente, el polvo puede ser suministrado a la separacion del rodillo dejandolo caer sobre la lamina continua en movimiento aguas arriba del rodillo y de su elevacion de choque. Alternativamente, el polvo puede ser suministradoIn a second type of powder supply, the powder can be provided, for example, on the upper surface of the continuous sheet upstream of a "nip", or separation of the roller, on the upstream side of the roller (for example, near the separation under the roller of the powder filling stage). Allowing an excess of dust to accumulate as a shock lift in the roller separation, the shock lift can act as a deposit, and ensure continuity and uniformity of the powder application process. Conveniently, the powder can be supplied to the roller separation by dropping it onto the continuous sheet moving upstream of the roller and its shock elevation. Alternatively, the powder can be supplied
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
(por ejemplo, dejandolo caer) directamente sobre la elevacion de choque del polvo justo aguas arriba del rodillo de la etapa de llenado de polvo. Tales suministros de polvo pueden ser continuos, pueden ser intermitentes o cambiar de velocidad. De manera deseable, la disposicion de alimentador de polvo es seleccionada de manera que durante el suministro de polvo, no se formen aglomerados grandes (por ejemplo 2 mm o mayores), por ejemplo para evitar que los aglomerados grandes alcancen la separacion del rodillo lo que podna producir la obstruccion de la entrada de polvo en la region de la separacion del rodillo y/o perturbaciones en el llenado. Las configuraciones de alimentacion de tornillo, disposiciones de tamiz vibrante, y disposiciones de cuarteador (divisores de muestra en polvo) son ejemplo de sistemas de alimentacion de polvo que pueden ser adecuados. De manera adecuada, la lamina continua es suministrada de manera continua a, y a traves de, la disposicion o etapa suministradora de polvo. De manera conveniente, como se muestra en la ilustracion esquematica de la Figura 1, una tolva vibrante (2) con una disposicion de alimentacion de tornillo (5) puede ser utilizada para llenar (dejar caer) polvo (4) sobre la lamina continua, a medida que la lamina continua se nueve a, y a traves de, la etapa de alimentacion de polvo (50).(for example, dropping it) directly on the dust shock elevation just upstream of the roller of the powder filling stage. Such dust supplies may be continuous, may be intermittent or change speed. Desirably, the powder feeder arrangement is selected so that during the powder delivery, large agglomerates (for example 2 mm or larger) are not formed, for example to prevent large agglomerates from reaching the separation of the roller which it could cause the obstruction of the dust inlet in the region of the separation of the roller and / or disturbances in filling. Screw feed configurations, vibrating screen arrangements, and quartered arrangements (powder sample dividers) are examples of powder feeding systems that may be suitable. Suitably, the continuous sheet is continuously supplied to, and through, the powder supply arrangement or stage. Conveniently, as shown in the schematic illustration of Figure 1, a vibrating hopper (2) with a screw feed arrangement (5) can be used to fill (drop) dust (4) onto the continuous sheet, as the sheet continues to nine, and through, the powder feed stage (50).
El suministrito de polvo no necesita ser esparcido lateralmente a traves de la anchura de la lamina, pero puede ser suministrada a solo una parte de la anchura de la lamina continua, por ejemplo puede ser suministrado a la lmea central de la lamina continua. Una vez que se ha acumulado una cantidad suficiente de polvo como una elevacion de choque sobre la superficie superior de la lamina continua en el rodillo, el polvo tiende a esparcirse el mismo lateralmente. Para una anchura de lamina continua de aproximadamente 150 mm, es tipicamente satisfactorio un unico suministro. Para laminas continuas mas anchas, o si se produce la segregacion lateral del polvo dentro de la elevacion de choque de polvo (por ejemplo si las partfculas mas gruesas o mas finas de una sustancia en polvo particular tienen una tendencia a moverse fuera de los bordes de la lamina continua de manera preferencial), entonces se pueden emplear multiples suministros a traves de la lamina continua. De manera alternativa, un unico suministro puede ser esparcido para producir un esparcido lateral ancho del polvo sobre la superficie superior de la lamina continua, por medio de un cuarteador giratorio o alternativo u otra disposicion adecuada.The powder supply does not need to be spread laterally across the width of the sheet, but it can be supplied to only a part of the width of the continuous sheet, for example it can be supplied to the central line of the continuous sheet. Once a sufficient amount of dust has accumulated as a shock elevation on the upper surface of the continuous sheet in the roller, the powder tends to spread it laterally. For a continuous sheet width of approximately 150 mm, a single supply is typically satisfactory. For continuous wider sheets, or if lateral segregation of the dust occurs within the dust shock elevation (for example if the thicker or finer particles of a particular powder substance have a tendency to move outside the edges of the sheet continues preferentially), then multiple supplies can be used through the continuous sheet. Alternatively, a single supply can be spread to produce a wide lateral spread of the powder on the upper surface of the continuous sheet, by means of a rotary or alternative quarterator or other suitable arrangement.
En lo que se refiere a la alternativa de suministrar polvo directamente al rodillo, aqrn el polvo puede ser suministrado directamente sobre el rodillo, tipicamente a traves de un suministro moderado, de manera que la capa de polvo continua sobre el rodillo se mantenga a la vez que es repuesta. Alternativamente, se puede utilizar una disposicion de pared aguas arriba del rodillo para contener un deposito de polvo en el lado aguas abajo del rodillo, desde la cual el rodillo puede recoger y suministrar (transportar) el polvo sobre sf mismo hasta la separacion del rodillo aguas arriba, en donde se puede incorporar a la capa de cubierta continua para mantener y reponer la capa. Aqrn, de nuevo es deseable que la disposicion de suministro de polvo sea seleccionada de manera que no permita que un exceso de polvo demasiado grande perturbe la capa en el rodillo ni permita que aglomerados grandes sean suministrados al rodillo y/o a la separacion del rodillo.With regard to the alternative of supplying powder directly to the roller, here the powder can be supplied directly on the roller, typically through a moderate supply, so that the continuous powder layer on the roller is maintained at the same time That is answered. Alternatively, a wall arrangement upstream of the roller can be used to contain a powder deposit on the downstream side of the roller, from which the roller can collect and deliver (transport) the powder on itself to the separation of the water roller above, where it can be incorporated into the continuous cover layer to maintain and replenish the layer. Here again, it is desirable that the powder supply arrangement be selected so that it does not allow too much excess dust to disturb the layer in the roller or allow large agglomerates to be supplied to the roller and / or to the separation of the roller.
Para ambos tipos de suministro de polvo, es deseable que el suministro de polvo sea realizado, para proporcionar una acumulacion de polvo sobre la lamina continua aguas arriba de, y adyacente al, rodillo (por ejemplo, en la separacion del rodillo). Tal acumulacion (por ejemplo en forma de elevacion de choque) puede actuar como un deposito de polvo, reponiendo la cubierta de polvo sobre la superficie exterior del rodillo, y de este modo, ayudando a asegurar la continuidad y uniformidad del proceso de llenado de polvo. Los procesos descritos aqrn pueden comprender de manera deseable o adicionalmente medios de control automatico para conectar o desconectar, o para modificar la velocidad del suministro de polvo. Ademas, el suministro del polvo puede ser controlado automaticamente de manera deseable como respuesta a un sensor o sensores, tal como un sensor o sensores que detecten la acumulacion de polvo (por ejemplo, la presencia y/o la cantidad de polvo) sobre el rodillo y/o la acumulacion de polvo (por ejemplo la presencia y/o la cantidad de polvo) sobre la lamina continua aguas arriba del rodillo, por ejemplo en la elevacion de choque. Por ejemplo, un sensor o sensores (por ejemplo sensor(es) capacitivo o sensor(es) reflectante de tipo opto-electronico se pueden utilizar convenientemente para controlar el espesor de la capa de revestimiento de polvo en el rodillo de rotacion. Ajustando la sensibilidad de tal sensor o sensores, la reduccion de esta capa de revestimiento se puede detectar antes de que se vuelva suficientemente no uniforme o reducida para proporcionar una uniformidad aceptable del revestimiento, de manera que el suministro de polvo se puede ajustar en consecuencia automaticamente para reponer la capa de cubierta en el rodillo. En combinacion con esto o alternativamente a ello, se ha encontrado ventajoso utilizar un sensor o sensores (por ejemplo un sensor(es) capacitivo(s) o un sensor(es) de trasmitancia de tipo opto-electronico de fuente/detector para detectar la cantidad de polvo acumulado aguas arriba del rodillo, por ejemplo en la elevacion de choque. Por ejemplo, una disposicion de espesor de par fuente/detector opto-electronico de tipo de transmitancia se ha demostrado altamente ventajoso para detectar la presencia de tal acumulacion de varios milfmetros de polvo delante del borde delantero de un rodillo de 23 mm de diametro. Tal sensor o sensores para la cantidad de acumulacion de polvo es/son bien adecuados para controlar la cantidad de polvo y para proporcionar retroalimentacion automatica para controlar el suministro de polvo (por ejemplo, conectando y desconectando un alimentador de polvo o haciendo variar la velocidad del suministro de polvo, etc.). Generalmente, en procesos en los que el polvo es suministrado sobre la superficie de la lamina continua aguas arriba del rodillo, es deseable que el alimentador este situado bastante cerca del rodillo, de manera que los retrasos de tiempo en el ajuste de suministro de polvo sean minimizados y por tanto el control tenga respuesta adecuada.For both types of powder supply, it is desirable that the powder supply be performed, to provide a build-up of dust on the continuous sheet upstream of, and adjacent to, the roller (for example, in the separation of the roller). Such accumulation (for example in the form of a shock lift) can act as a dust deposit, replenishing the dust cover on the outer surface of the roller, and thus helping to ensure the continuity and uniformity of the powder filling process. . The processes described herein may desirably or additionally comprise automatic control means for connecting or disconnecting, or for modifying the speed of the powder supply. In addition, the powder supply may be desirably automatically controlled in response to a sensor or sensors, such as a sensor or sensors that detect the accumulation of dust (e.g., the presence and / or the amount of dust) on the roller. and / or the accumulation of dust (for example the presence and / or the amount of dust) on the continuous sheet upstream of the roller, for example in the elevation of shock. For example, a sensor or sensors (for example capacitive sensor (s) or opto-electronic reflective sensor (s) can be conveniently used to control the thickness of the powder coating layer on the rotation roller. Adjusting the sensitivity of such a sensor or sensors, the reduction of this coating layer can be detected before it becomes sufficiently non-uniform or reduced to provide an acceptable uniformity of the coating, so that the powder supply can be adjusted accordingly automatically to replenish the cover layer on the roller In combination with this or alternatively, it has been found advantageous to use a sensor or sensors (for example a capacitive sensor (s) or a transmission sensor (s) of opto-electronic type source / detector to detect the amount of dust accumulated upstream of the roller, for example in the elevation of shock, for example, an arrangement of torque thickness f Opto-electronic source / transmitter of transmittance type has proved highly advantageous for detecting the presence of such accumulation of several millimeters of dust in front of the leading edge of a 23 mm diameter roller. Such a sensor or sensors for the amount of dust accumulation is / are well suited to control the amount of dust and to provide automatic feedback to control the dust supply (for example, by connecting and disconnecting a powder feeder or by varying the speed of the powder supply, etc.). Generally, in processes in which the powder is supplied on the surface of the continuous sheet upstream of the roller, it is desirable that the feeder is located quite close to the roller, so that the time delays in the powder supply adjustment are minimized and therefore the control has adequate response.
Los procesos descritos aqrn incluyen un recipiente de polvo sobre la lamina continua y en el rodillo. Por ejemplo, se pueden conseguir de manera conveniente disponiendo placas verticales o cunas de metal en ambos lados de la lamina continua de material laminar en movimiento con el fin de confinar lateralmente el polvo. (El confinamientoThe processes described here include a dust container on the continuous sheet and on the roller. For example, they can be conveniently achieved by arranging vertical plates or metal cradles on both sides of the continuous sheet of moving sheet material in order to laterally confine the powder. (The confinement
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
vertical es, por supuesto, proporcionado por la propia lamina continua y por la gravedad, y un confinamiento longitudinal adecuado se proporciona por el movimiento de la lamina continua y por la naturaleza del propio proceso). De manera deseable, las placas verticales pueden estar suavemente cargadas contra los bordes de la lamina continua, para permitir diferencias en el giro lateral de la lamina continua en el tiempo a la vez que se evita el doblado significativo de la lamina continua. De manera conveniente, se pueden emplear laminas de caucho cargadas.vertical is, of course, provided by the continuous sheet itself and by gravity, and adequate longitudinal confinement is provided by the movement of the continuous sheet and by the nature of the process itself). Desirably, the vertical plates may be gently loaded against the edges of the continuous sheet, to allow for differences in the lateral rotation of the continuous sheet over time while avoiding significant bending of the continuous sheet. Conveniently, loaded rubber sheets can be used.
Volviendo de nuevo a la Figura 1 que proporciona una ilustracion esquematica de un proceso a modo de ejemplo de acuerdo con la invencion, se aprecia que el rodillo accionado (12) de la etapa de llenado de polvo (15) esta girando alrededor de un eje generalmente transversal a la direccion del movimiento de la lamina continua. De manera deseable el rodillo esta girando en la misma direccion que la del movimiento general de la lamina continua (como se indica con la flecha (10)) y por tanto en la direccion de la flecha (14). Ademas, como se puede apreciar en la Figura 1, existe una separacion estrecha (16) entre la superficie exterior del rodillo (12) y la superficie superior de la lamina continua (8). En la realizacion a modo de ejemplo de la Figura 1, la aplicacion de una placa de base solida (18) debajo y separada apropiadamente del rodillo para formar una pasaje (6) permite un posicionamiento del rodillo (12) y la lamina continua (8) uno con relacion al otro, de tal manera que se proporciona una separacion (16) entre la superficie exterior del rodillo y la superficie superior (hacia el rodillo) de la lamina continua. En particular, en la realizacion a modo de ejemplo de la Figura 1, cuando la lamina continua (8) atraviesa el pasaje (6) entre el rodillo (12) y la base (18), el polvo (4) sobre la lamina continua forma una acumulacion (7) aguas arriba del rodillo (12) y la separacion (16) esta dispuesta entre la superficie exterior del rodillo y la superficie superior de la lamina continua. El posicionamiento del rodillo y la lamina continua uno con relacion al otro para proporcionar una separacion entre los dos se puede conseguir por otros medios adecuados, tales como sustituir la placa de base ilustrada de la Figura 1 por otros tipos de elementos de base (por ejemplo, una serie de rodillos no accionados, configuracion de cinta o una hoja de rascado o un segundo rodillo (que puede ser o no accionado)) opuesto al rodillo accionado de la etapa de llenado de polvo, de manera que se proporciona un pasaje para la lamina continua entre el rodillo y la base.Turning again to Figure 1, which provides a schematic illustration of an exemplary process according to the invention, it can be seen that the driven roller (12) of the powder filling stage (15) is rotating about an axis generally transverse to the direction of movement of the continuous sheet. Desirably, the roller is rotating in the same direction as that of the general movement of the continuous sheet (as indicated by the arrow (10)) and therefore in the direction of the arrow (14). In addition, as can be seen in Figure 1, there is a narrow gap (16) between the outer surface of the roller (12) and the upper surface of the continuous sheet (8). In the exemplary embodiment of Figure 1, the application of a solid base plate (18) under and properly separated from the roller to form a passage (6) allows a positioning of the roller (12) and the continuous sheet (8 ) one in relation to the other, such that a separation (16) between the outer surface of the roller and the upper surface (towards the roller) of the continuous sheet is provided. In particular, in the exemplary embodiment of Figure 1, when the continuous sheet (8) crosses the passage (6) between the roller (12) and the base (18), the powder (4) on the continuous sheet it forms an accumulation (7) upstream of the roller (12) and the separation (16) is disposed between the outer surface of the roller and the upper surface of the continuous sheet. The positioning of the roller and the sheet continues relative to each other to provide a separation between the two can be achieved by other suitable means, such as replacing the base plate illustrated in Figure 1 with other types of base elements (for example , a series of non-driven rollers, tape configuration or a scraper blade or a second roller (which may or may not be driven)) opposite the driven roller of the powder filling stage, so that a passage for the continuous sheet between the roller and the base.
Mediante la provision de una separacion junto con la aplicacion de una velocidad de superficie de rodillo que es diferente, preferiblemente mayor, que la velocidad de la lamina continua, durante el funcionamiento del proceso, una capa continua y visualmente uniforme de polvo se acumula rapidamente en la superficie exterior del rodillo. La presencia de una capa de polvo continua y visualmente uniforme sobre el rodillo, cuya formacion se cree que es (aunque no se desea que este limitado por ninguna teona) causada por la accion de cizalla del polvo de las velocidades diferentes de la superficie del rodillo y la lamina continua en presencia de la separacion entre los dos, permite el empaquetamiento deseablemente preciso y uniforme del polvo en las depresiones. La formacion de esta capa de polvo es ademas facilitada de manera favorable por la rotacion de la superficie del rodillo en la misma direccion general que el movimiento de la lamina continua. Volviendo a la realizacion a modo de ejemplo mostrada en la Figura 1, se apreciara en el inicio del llenado, cuando la lamina continua (8) y el polvo (4) atraviesan el pasaje (6), que la lamina continua se movera alejandose de la superficie exterior del rodillo (12) hacia la placa de base (18) para proporcionar una separacion (16) entre el rodillo y la lamina continua, y (poco despues) una vez que la capa continua de polvo (9) forme la superficie exterior del rodillo, esta capa de polvo a su vez mantiene la separacion entre el rodillo y la lamina continua.By providing a separation together with the application of a roller surface speed that is different, preferably greater, than the speed of the continuous sheet, during the operation of the process, a continuous and visually uniform layer of dust quickly accumulates in The outer surface of the roller. The presence of a continuous and visually uniform layer of dust on the roller, the formation of which is believed to be (although it is not desired that it be limited by any teona) caused by the shear action of the powder at different speeds of the roller surface and the continuous sheet in the presence of the separation between the two, allows desirably accurate and uniform packing of the powder in the depressions. The formation of this powder layer is also favorably facilitated by the rotation of the surface of the roller in the same general direction as the movement of the continuous sheet. Returning to the exemplary embodiment shown in Figure 1, it will be appreciated at the beginning of the filling, when the continuous sheet (8) and the powder (4) pass through the passage (6), that the continuous sheet will move away from the outer surface of the roller (12) towards the base plate (18) to provide a separation (16) between the roller and the continuous sheet, and (shortly after) once the continuous layer of powder (9) forms the surface Outside the roller, this layer of dust in turn maintains the separation between the roller and the continuous sheet.
La anchura de separacion generalmente tiende a afectar al espesor de la capa de polvo que se forma en el rodillo giratorio en el proceso. Tfpicamente, el espesor de la capa de polvo formada en el rodillo es similar a la anchura de separacion. Se apreciara que para las realizaciones que emplean una base en combinacion con el rodillo de la etapa de llenado de polvo para proporcionar un pasaje y, de este modo el posicionamiento respectivo de la lamina continua y el rodillo, como se ha descrito anteriormente o mostrado en las realizacion a modo de ejemplo de la Figura 1, la anchura de separacion es tipicamente la anchura del paso menos el espesor de la lamina continua. La seleccion de la anchura de separacion particular depende de un cierto numero de factores, tales como las propiedades del polvo particular que esta siendo llenado, las dimensiones y el patron de las microdepresiones que van a ser llenadas, y el espesor de la lamina continua y su variacion de espesor. Por ejemplo, sulfato de albuterol micronizado con un diametro de partfcula de masa media de aproximadamente 2 a 3 micras y con al menos un 95% de partfculas en masa que tiene un diametro menor de 5 micras ha sido depositado satisfactoriamente en las microdepresiones de una material lamina de 0,2 mm de espesor utilizando una anchura de separacion de 0,65 mm, mientras que monohidrato de lactosa micronizado de una distribucion de tamano de partfcula similar ha sido satisfactoriamente depositado en el mismo material laminar en separaciones de 0,45 mm y 0,65 mm. Generalmente, se ha encontrado que la formacion de una cubierta estable, sustancial, de polvo sobre el rodillo se facilita de forma deseable a traves de la aplicacion de una anchura de separacion de 1,25 mm o menor, mas deseablemente 1,00 mm o menor y lo mas deseable 0,75 mm o menor. Para facilitar el mantenimiento de una cubierta estable de polvo sobre el rodillo junto con un proceso deseable continuo suave de suministro y llenado de la lamina continua, la aplicacion de una anchura de separacion de 0,2 mm o mayor es deseable, 0,3 o mayor es mas deseable y 0,4 mm o mayor lo mas deseable. Como se ha mencionado anteriormente, la inclusion de un elemento de flexibilidad en el posicionamiento del rodillo y la lamina continua se ha encorado que es ventajoso, de manera que la separacion es variable en anchura. Por ejemplo, para facilitar la prevencion de la formacion de presiones elevadas en el rodillo, debido a la acumulacion de polvo en la separacion, el posicionamiento del rodillo y la lamina continua se puede disponer de tal manera que la separacion este cargada hacia la anchura minima predeterminada, por ejemplo a traves del uso de muelles, pero al mismo tiempo permitiendo alguna variabilidad en la anchura de separacion, porThe separation width generally tends to affect the thickness of the powder layer that forms on the rotating roller in the process. Typically, the thickness of the powder layer formed in the roller is similar to the separation width. It will be appreciated that for embodiments that employ a base in combination with the roller of the powder filling stage to provide a passage and, thus, the respective positioning of the continuous sheet and the roller, as described above or shown in As an exemplary embodiment of Figure 1, the separation width is typically the width of the passage minus the thickness of the continuous sheet. The selection of the particular separation width depends on a number of factors, such as the properties of the particular powder being filled, the dimensions and pattern of the microdepressions to be filled, and the thickness of the continuous sheet and its thickness variation. For example, micronized albuterol sulfate with a particle diameter of average mass of approximately 2 to 3 microns and with at least 95% of mass particles having a diameter of less than 5 microns has been successfully deposited in the microdepressions of a material 0.2 mm thick sheet using a separation width of 0.65 mm, while micronized lactose monohydrate of a similar particle size distribution has been successfully deposited in the same sheet material in 0.45 mm separations and 0.65 mm. Generally, it has been found that the formation of a stable, substantial, dust cover on the roller is desirably facilitated through the application of a separation width of 1.25 mm or less, more desirably 1.00 mm or smaller and most desirable 0.75 mm or less. To facilitate the maintenance of a stable dust cover on the roller together with a smooth continuous continuous process of supply and filling of the continuous sheet, the application of a separation width of 0.2 mm or greater is desirable, 0.3 or greater is more desirable and 0.4 mm or greater the most desirable. As mentioned above, the inclusion of an element of flexibility in the positioning of the roller and the continuous sheet has been found to be advantageous, so that the separation is variable in width. For example, to facilitate the prevention of the formation of high pressures in the roller, due to the accumulation of dust in the separation, the positioning of the roller and the continuous sheet can be arranged such that the separation is loaded towards the minimum width predetermined, for example through the use of springs, but at the same time allowing some variability in the separation width, by
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
ejemplo, el movimiento hacia una anchura de separacion mayor.For example, the movement towards a greater separation width.
La formacion de una cubierta de polvo estable, sustancial sobre el rodillo es, de manera deseable, facilitada adicionalmente mediante la provision de una velocidad de superficie de rodillo que sea mayor que la velocidad de la lamina continua en la posicion del rodillo. Tambien se ha encontrado que, con el fin de minimizar el riesgo de bloqueo del polvo en la separacion (y el resigo de fallo posterior del proceso y posible rotura de la lamina continua), el uso de una velocidad de superficie de rodillo que exceda la velocidad de la lamina continua en un factor mmimo de 1,1 (es decir en una relacion de al menos 1,1 a 1) es ventajoso. Se ha encontrado que un regimen de relacion de velocidad optimo depende de un cierto numero de factores, tales como la velocidad de la lamina continua, el diametro del rodillo, las caractensticas del polvo, las caractensticas de la superficie de la lamina continua, y la anchura de separacion. Por ejemplo, se ha observado que cuando la velocidad de lamina continua aumenta, la relacion optima de la velocidad de superficie del rodillo respecto a la velocidad de la lamina continua tambien aumenta. En general, una relacion entre la velocidad de superficie de rodillo y la velocidad de superficie de lamina continua de al menos 1,1 a 1 es adecuada, al menos 2 a 1 es mas adecuada y al menos 3 a 1 es la mas adecuada. Para la estabilidad del proceso global se ha encontrado que es ventajoso aplicar una relacion entre la velocidad de superficie de rodillo y la velocidad de lamina continua de al menos 10 a 1 o menor, mas adecuadamente al menos 7 a 1, y lo mas adecuado al menos 5 a 1.The formation of a stable, substantial powder cover on the roller is desirably further facilitated by the provision of a roller surface speed that is greater than the speed of the continuous sheet at the roller position. It has also been found that, in order to minimize the risk of blockage of dust in the separation (and the risk of subsequent process failure and possible breakage of the continuous sheet), the use of a roller surface speed that exceeds the Continuous sheet speed at a minimum factor of 1.1 (ie in a ratio of at least 1.1 to 1) is advantageous. It has been found that an optimal speed ratio regime depends on a number of factors, such as the speed of the continuous sheet, the diameter of the roller, the characteristics of the powder, the characteristics of the surface of the continuous sheet, and the separation width. For example, it has been observed that when the continuous sheet speed increases, the optimum ratio of the surface speed of the roller to the speed of the continuous sheet also increases. In general, a relationship between the roller surface speed and the continuous sheet surface speed of at least 1.1 to 1 is adequate, at least 2 to 1 is more suitable and at least 3 to 1 is the most appropriate. For the stability of the overall process it has been found that it is advantageous to apply a relationship between the roller surface speed and the continuous sheet speed of at least 10 to 1 or less, more suitably at least 7 to 1, and most suitable at minus 5 to 1.
Las velocidades de lamina continua de 3 metros por minuto o mayores son generalmente adecuadas, mientras que para regfmenes de produccion mayores y generalmente estabilidad de proceso mejor, son deseables velocidades de lamina continua de al menos 10 metros por minuto, al menos 15 por minuto mas deseables, y al menos 17 metros por minuto las mas deseables. Generalmente, una velocidad de lamina continua maxima adecuada es 25 metros por minuto. Para velocidades de lamina continua de aproximadamente 20 a 25 metros por minuto, generalmente la relacion entre la velocidad de superficie de rodillo y la velocidad de lamina continua es deseablemente de al menos 3:1. Para mejorar mas el proceso global y la fiabilidad del llenado, puede ser deseable acoplar automaticamente la velocidad de superficie del rodillo a la velocidad de la lamina continua. Por ejemplo, a traves de tal acoplamiento la relacion entre la velocidad optima y/o deseada y la velocidad de superficie del de rodillo y la velocidad de lamina continua se puede mantener durante los cambios en la velocidad de lamina continua y/o velocidad de superficie de rodillo. Para minimizar cualquier tendencia potencial al atascamiento de proceso, por ejemplo a traves del bloqueo del polvo en la separacion, deseablemente la velocidad de lamina continua generalmente es mantenida sin fluctuaciones de velocidad significativas (es decir, como mucho un 10%, mas adecuadamente como mucho un 7% y lo mas adecuado como mucho un 3% de fluctuacion de velocidad). Se ha encontrado que para un rodillo que tiene un diametro de 20 mm o mayor, la aplicacion de velocidades de lamina continua de al menos 10 metros por minuto mejora la uniformidad asf como como la estabilidad del proceso de llenado.Continuous sheet speeds of 3 meters per minute or greater are generally adequate, while for higher production rates and generally better process stability, continuous sheet speeds of at least 10 meters per minute, at least 15 per minute more are desirable. desirable, and at least 17 meters per minute the most desirable. Generally, a suitable maximum continuous sheet speed is 25 meters per minute. For continuous sheet speeds of about 20 to 25 meters per minute, generally the ratio between the roller surface speed and the continuous sheet speed is desirably at least 3: 1. To further improve the overall process and the reliability of the filling, it may be desirable to automatically couple the surface speed of the roller to the speed of the continuous sheet. For example, through such coupling the relationship between the optimum and / or desired speed and the surface speed of the roller and the continuous sheet speed can be maintained during changes in the continuous sheet speed and / or surface speed. of roller. To minimize any potential tendency to process clogging, for example through blockage of dust in the separation, desirably the continuous sheet speed is generally maintained without significant speed fluctuations (i.e., at most 10%, more adequately as much 7% and most suitable as much 3% speed fluctuation). It has been found that for a roller having a diameter of 20 mm or greater, the application of continuous sheet speeds of at least 10 meters per minute improves uniformity as well as the stability of the filling process.
De manera adecuada, el rodillo es de seccion circular, en particular sin ninguna parte aplanada. El rodillo puede tener un diametro de hasta 150 mm. Se ha encontrado que rodillos de diametros mas pequenos son ventajosos para proporcionar las geometnas deseables en la separacion del rodillo con relacion a la lamina continua y de este modo las fuerzas de cizalla deseables para el llenado del polvo. Por consiguiente, el rodillo deseable tiene un diametro de 60 mm o menor, de manera mas deseable 40 mm o menor, incluso de manera mas deseable 30 mm o menor y lo mas deseable 25 mm o menor. Para ayudar a minimizar la aceleracion centnfuga a cualquier velocidad de superficie de rodillo dada (y de este modo minimizar el potencial de que las partfculas de polvo sean impulsadas desde la superficie del rodillo como resultado de tal aceleracion centnfuga), se ha encontrado deseable el uso de un rodillo con un diametro de 8 mm o mayor, de manera mas deseable 10 mm o mayor, incluso de manera mas deseable 15 mm o mayor, y lo mas deseable 20 mm o mayor.Suitably, the roller is circular in section, in particular without any flattened parts. The roller can have a diameter of up to 150 mm. It has been found that smaller diameter rollers are advantageous to provide desirable geometries in the separation of the roller relative to the continuous sheet and thus the desirable shear forces for powder filling. Therefore, the desirable roller has a diameter of 60 mm or less, more desirably 40 mm or less, even more desirably 30 mm or less and most desirably 25 mm or less. To help minimize the centrifugal acceleration at any given roller surface speed (and thereby minimize the potential for dust particles to be driven from the roller surface as a result of such centrifugal acceleration), use has been found desirable. of a roller with a diameter of 8 mm or greater, more desirably 10 mm or greater, even more desirably 15 mm or greater, and most desirably 20 mm or greater.
La superficie del rodillo es adecuadamente dura y ngida. Los rodillos pueden comprender de manera adecuada una superficie de metal, por ejemplo un rodillo de metal macizo o un rodillo provisto de una superficie de metal. Tambien se ha encontrado deseable que la superficie del rodillo sea generalmente lisa, por ejemplo, sin gravados, y sin estar provista de ninguna estructura elevada. Por ejemplo se ha encontrado que un rodillo de acero inoxidable macizo y liso es particularmente adecuado para utilizar en el proceso. Otros materiales, tales como aleaciones de aluminio, se pueden utilizar para el rodillo.The surface of the roller is adequately hard and sharp. The rollers can suitably comprise a metal surface, for example a solid metal roller or a roller provided with a metal surface. It has also been found desirable that the surface of the roller be generally smooth, for example, without encumbrances, and without being provided with any elevated structure. For example, it has been found that a solid and smooth stainless steel roller is particularly suitable for use in the process. Other materials, such as aluminum alloys, can be used for the roller.
Como se ha mencionado anteriormente, para incluso una mayor facilidad en el llenado asf como para hacer el proceso mas fiable y estable, se ha encontrado deseable suministrar la lamina continua a, y desde, el rodillo, de manera que en el rodillo la lamina continua atraviese un quiebro de manera que exista un angulo de contacto de menos de 180° hacia el rodillo. Aqrn, la lamina continua es suministrada de manera deseable generalmente a lo largo de un primer plano y desde el rodillo generalmente a lo largo de un segundo plano, definiendo la interseccion del primer y segundo planos en el rodillo un angulo menor de 180°, hacia el rodillo. Haciendo referencia a la realizacion a modo de ejemplo en el Figura 1, se puede observar que el movimiento de lamina continua total es de izquierda a derecha a lo largo de un plano horizontal como se indica con la flecha (10), y hacia el rodillo (12) la lamina continua (8) esta siendo suministrada a lo largo del plano horizontal, mientras que desde el rodillo la lamina continua esta siendo suministrada a lo largo de un plano que tiene una inclinacion hacia arriba con relacion a la horizontal. Esto se puede apreciar mejor en la Figura 2 que proporciona un dibujo esquematico de solo la alimentacion de la lamina continua (8) a, y desde, el rodillo (12) de la realizacion a modo de ejemplo de la Figura 1. (Para una facil visualizacion, el rodillo se muestra en lmeas de trazos, aunque el polvo, la base, etc. no se muestran en el dibujo esquematico.). Aqrn, la lamina continua (8) es alimentada al rodillo (12) a lo largo de un plano designadoAs mentioned above, for even greater ease in filling as well as to make the process more reliable and stable, it has been found desirable to supply the continuous sheet to, and from, the roller, so that in the roller the continuous sheet go through a break so that there is a contact angle of less than 180 ° towards the roller. Here, the continuous sheet is desirably supplied generally along a first plane and from the roller generally along a second plane, the intersection of the first and second planes in the roller defining an angle less than 180 °, towards the roller Referring to the exemplary embodiment in Figure 1, it can be seen that the total continuous sheet movement is from left to right along a horizontal plane as indicated by the arrow (10), and towards the roller (12) the continuous sheet (8) is being supplied along the horizontal plane, while from the roller the continuous sheet is being supplied along a plane that has an upward inclination relative to the horizontal. This can best be seen in Figure 2 which provides a schematic drawing of only the continuous sheet feed (8) to, and from, the roller (12) of the exemplary embodiment of Figure 1. (For a Easy visualization, the roller is shown in dashed lines, although dust, base, etc. are not shown in the schematic drawing.). Here, the continuous sheet (8) is fed to the roller (12) along a designated plane
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
como A y sale del rodillo a lo largo de un segundo plano designado B, y la interseccion de estos pianos en el rodillo definen un angulo de contacto (a) hacia el rodillo, siendo el angulo aproximadamente 173° en la realizacion a modo de ejemplo.as A and exits the roller along a designated second plane B, and the intersection of these pianos in the roller define a contact angle (a) towards the roller, the angle being approximately 173 ° in the exemplary embodiment .
De nuevo se cree que la provision de tal angulo de contacto de menos de 180° permite una envuelta parcial alrededor de la lamina continua en el rodillo proporcionando un componente de fuerza directamente normal a la capa de polvo sobre el rodillo. Ademas, se cree que cuando la lamina continua atraviesa un quiebro en el rodillo, por ejemplo un angulo de contacto menor de 180°, mas preferiblemente 177° o menor, lo mas preferible 175° o menor, entonces una fuerza contribuye al proceso de llenado por la tension de la lamina continua, como un componente de la tension de la lamina continua normal a la capa de cubierta de polvo sobre el rodillo, y que esto mejora el llenado y la estabilidad y fiabilidad del proceso. Angulos de contacto mas pequenos generalmente confieren mayor estabilidad al proceso de llenado. Sin embargo, para minimizar la friccion, el desgaste de componente, y el riesgo de rotura de la lamina continua, de manera deseable, el angulo de contacto es de 150° o mayor, de manera mas deseable 160° o mayor, y lo mas deseable 170° o mayor.Again, it is believed that the provision of such a contact angle of less than 180 ° allows a partial wrap around the continuous sheet in the roller providing a force component directly normal to the powder layer on the roller. Furthermore, it is believed that when the continuous sheet passes through a break in the roller, for example a contact angle of less than 180 °, more preferably 177 ° or less, most preferably 175 ° or less, then a force contributes to the filling process. by the tension of the continuous sheet, as a component of the tension of the continuous sheet normal to the dust cover layer on the roller, and that this improves the filling and the stability and reliability of the process. Smaller contact angles generally confer greater stability to the filling process. However, to minimize friction, component wear, and the risk of continuous sheet breakage, desirably, the contact angle is 150 ° or greater, more desirably 160 ° or greater, and the most desirable 170 ° or higher.
Se aprecia que la provision del angulo de contacto deseado se puede conseguir utilizando otras configuraciones de suministro de lamina continua a, y desde, el rodillo distintas a las de las Figuras 1 y 2, que muestran la lamina continua siendo alimentada al rodillo a lo largo de un plano horizontal y alejandose del rodillo a lo largo de un plano que tiene una inclinacion hacia arriba con relacion a la horizontal. Por ejemplo, la lamina continua puede ser suministrada al rodillo a lo largo de un plano que tenga una pendiente hacia abajo con relacion a la horizontal (por ejemplo en una diferencia de 4° con la horizontal) y suministrada desde el rodillo a lo largo de la horizontal (es decir, una diferencia de 0° con la horizontal) o a lo largo de un plano que tenga una inclinacion hacia arriba con relacion a la horizontal (por ejemplo una diferencia de 8° con la horizontal) para proporcionar un angulo de menos de 180° hacia el rodillo (por ejemplo un angulo de contacto de 176° o 168°, respetivamente). Es posible suministrar la lamina continua desde el rodillo a lo largo de un plano que tenga una inclinacion hacia abajo con relacion a la horizontal (por ejemplo, en una diferencia de 5° con la horizontal) cuando la lamina continua es suministrada al rodillo a lo largo de un plano que tiene una inclinacion hacia abajo con la horizontal en una inclinacion apropiada (por ejemplo en una diferencia de 15° con la horizontal) de manera que se proporciona un angulo de contacto menor de 180° hacia el rodillo (por ejemplo un angulo de contacto de 170°). Correspondientemente, tambien es posible suministrar la lamina continua al rodillo a lo largo de un plano que tiene una inclinacion hacia arriba con relacion a la horizontal (por ejemplo en una diferencia de 5° con la horizontal), cuando la lamina continua es suministrada desde el rodillo a lo largo de un plano que tiene una inclinacion hacia arriba con relacion a la horizontal en una inclinacion apropiada (por ejemplo en una diferencia de 13° con la horizontal) de manera que se proporciona un angulo de contacto menor de 180° hacia el rodillo (por ejemplo un angulo de contacto de 172°).It is appreciated that provision of the desired contact angle can be achieved using other continuous sheet supply configurations to, and from, the roller other than those of Figures 1 and 2, which show the continuous sheet being fed to the roller along of a horizontal plane and moving away from the roller along a plane that has an upward inclination in relation to the horizontal. For example, the continuous sheet can be supplied to the roller along a plane that has a downward slope relative to the horizontal (for example in a difference of 4 ° with the horizontal) and supplied from the roller along the horizontal (that is, a difference of 0 ° with the horizontal) or along a plane that has an upward inclination relative to the horizontal (for example a difference of 8 ° with the horizontal) to provide an angle of less 180 ° towards the roller (for example a contact angle of 176 ° or 168 °, respectively). It is possible to supply the continuous sheet from the roller along a plane that has a downward inclination relative to the horizontal (for example, in a difference of 5 ° with the horizontal) when the continuous sheet is supplied to the roller at along a plane that has an inclination downwards with the horizontal at an appropriate inclination (for example in a difference of 15 ° with the horizontal) so that a contact angle of less than 180 ° is provided towards the roller (for example a 170 ° contact angle). Correspondingly, it is also possible to supply the continuous sheet to the roller along a plane that has an upward inclination with respect to the horizontal (for example in a difference of 5 ° with the horizontal), when the continuous sheet is supplied from the roller along a plane that has an upward inclination relative to the horizontal at an appropriate inclination (for example in a difference of 13 ° with the horizontal) so that a contact angle of less than 180 ° is provided towards the roller (for example a contact angle of 172 °).
Se apreciara que para un material en polvo dado que va ser depositado en las microdepresiones en una lamina continua particular, se puede utilizar alguna experimentacion basica para determinar las combinaciones adecuadas de las variables del proceso tales como la anchura de separacion, la velocidad de lamina continua, la velocidad de superficie del rodillo y el diametro del rodillo y, si es aplicable el angulo de contacto y la tension de la lamina continua. Por ejemplo, para el llenado con polvo de sulfato de albuterol micronizado con un diametro de partfcula de masa media de alrededor de 2 a 3 micras y con al menos el 95% de sus partfculas en masa teniendo diametros por debajo de 5 micras en las microdepresiones discretas (50 micras de profundidad y 140 micras de anchura en la superficie superior) en un espesor de lamina continua de papel kraft revestida de LPDE (polietileno de baja densidad) de 0,2 mm de espesor, el uso de una velocidad de lamina continua de 10 metros por minuto junto con un rodillo de acero inoxidable pulido de 23 mm de diametro que gira con una velocidad de superficie de aproximadamente 3,5 veces la velocidad de lamina continua, una anchura de separacion de 0,65 mm y un angulo de contacto de aproximadamente 171,5° con la lamina continua siendo suministrada al rodillo horizontalmente, proporcionan un proceso estable y robusto con una precision adecuada y llenado uniforme de las microdepresiones.It will be appreciated that for a powder material since it will be deposited in the microdepressions in a particular continuous sheet, some basic experimentation can be used to determine the appropriate combinations of the process variables such as the separation width, the continuous sheet speed , the surface speed of the roller and the diameter of the roller and, if applicable, the contact angle and the tension of the continuous sheet. For example, for filling with micronized albuterol sulfate powder with an average mass particle diameter of about 2 to 3 microns and with at least 95% of its mass particles having diameters below 5 microns in microdepressions discrete (50 microns deep and 140 microns wide on the upper surface) on a continuous sheet thickness of kraft paper coated with LPDE (low density polyethylene) 0.2 mm thick, using a continuous sheet speed 10 meters per minute together with a 23 mm diameter polished stainless steel roller that rotates with a surface speed of approximately 3.5 times the continuous sheet speed, a separation width of 0.65 mm and an angle of Approximately 171.5 ° contact with the sheet continues to be supplied to the roller horizontally, providing a stable and robust process with adequate precision and uniform filling of the microdepressions.
Los procesos aqrn incluyen de manera adecuada una etapa adicional de retirar de la superficie de la lamina continua el exceso de polvo no depositado dentro de las depresiones y que permanece en areas de la superficie entre las depresiones. Tal retirada se puede conseguir por ejemplo utilizando una o mas chuchillas rascadoras para rascar el polvo residual que permanece en la superficie de la lamina continua entre las depresiones. Tales cuchillas rascadoras pueden estar fabricadas de manera deseable de metal (por ejemplo acero inoxidable), pueden ser materiales polimericos (por ejemplo polietileno) y/o elastomericos (elastomerico termoplastico o termoendurecible). De manera conveniente comprenden laminas de caucho flexibles de espesor comprendido entre 1 y 3 mm, soportadas en un angulo respecto a la lamina continua en movimiento. Un angulo comprendido entre 10° y 60° respecto a la lamina continua puede ser preferible, mas particularmente entre 40° y 50°. Convenientemente, las laminas de caucho pueden estar sujetas entre placas ngidas paralelas, con una parte de su longitud sobresaliendo. Una disposicion de limpia-superficies de hojas rascadoras de caucho que esta en contacto con la superficie superior de la lamina continua en movimiento se muestra en la realizacion a modo de ejemplo de la Figura 1. La lamina continua (8) se mueve en la direccion de la flecha (10) debajo de las dos hojas rascadoras (20, 30). Cada limpia- superficies de hoja rascadora (31), que puede ser una lamina de caucho de nitrilo de 1,5 mm de espesor y aproximadamente una dureza Shore A de 70, esta sujeta de forma deseable entre las placas ngidas (34, 36). La placa hacia la lamina continua (34) generalmente tiene un bisel, para asegurar que no puede entrar en contacto y danar la lamina continua. El limpiador de superficies de hoja rascadora (31) sobresale de manera deseable aproximadamente de 3 mm a 6 mm pasado el extremo de la placa hacia la lamina continua (34) y aproximadamenteAqrn processes suitably include an additional step of removing excess dust not deposited within the depressions from the surface of the sheet and remaining in surface areas between the depressions. Such removal can be achieved for example by using one or more scraper blades to scrape off the residual dust that remains on the surface of the continuous sheet between the depressions. Such scraper blades may be desirably made of metal (for example stainless steel), may be polymeric materials (for example polyethylene) and / or elastomeric materials (thermoplastic or thermosetting elastomeric). Conveniently they comprise flexible rubber sheets of thickness between 1 and 3 mm, supported at an angle to the continuous sheet in motion. An angle between 10 ° and 60 ° with respect to the continuous sheet may be preferable, more particularly between 40 ° and 50 °. Conveniently, the rubber sheets may be held between parallel nested plates, with a portion of their length protruding. A surface cleaning arrangement of rubber scraper blades that is in contact with the upper surface of the continuous moving sheet is shown in the exemplary embodiment of Figure 1. The continuous sheet (8) moves in the direction of the arrow (10) under the two scraper blades (20, 30). Each scraper blade surface cleaner (31), which can be a 1.5 mm thick nitrile rubber sheet and approximately a Shore A hardness of 70, is desirably secured between the nested plates (34, 36) . The plate towards the continuous sheet (34) generally has a bevel, to ensure that it cannot come into contact and damage the continuous sheet. The scraper blade surface cleaner (31) desirably protrudes approximately 3 mm to 6 mm past the end of the plate towards the continuous sheet (34) and approximately
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
6 mm pasado el extremo de la otra placa (36), estando las placas en un angulo de 45° respecto a la lamina continua, y su altura vertical con relacion a la lamina continua siendo elegida para asegurar un buen contacto del borde de limpieza (32) del limpia-superficies de hoja rascadora (31) con la lamina continua a la vez que se evitan excesivas fuerzas de friccion sobre la lamina continua. Sin embargo, sera evidente, que se podnan concebir muchas configuraciones alternativas. La extraccion con vado del polvo retirado de alrededor de los borde (32) del limpiador de superficies de hoja rascadora (31) se puede utilizar convenientemente para asegurar que el proceso continua uniformemente y consistentemente para retirar el exceso de polvo. El polvo recogido se puede hacer recircular desde el extremo delantero del proceso para los tipos de polvo que no esten degradados o alterados por el paso a traves del proceso. Como se puede apreciar en la Figura 1, puede ser deseable utilizar una hoja rascadora (40) sobre la superficie inferior de la lamina continua para retirar cualquier polvo que haya quedado sobre la superficie inferior de la lamina continua durante el procesado. Dos hojas por encima de la lamina continua, con una debajo de ella situada entre las mismas, se ha encontrado que es particularmente satisfactorio. Sus posiciones y alturas se pueden elegir de manera preferida para asegurar un buen contacto de la lamina continua con cada una, mientras se mantiene la curvatura o desviacion de la lamina continua en un mmimo, para evitar fuerzas de friccion grandes y otras fuerzas. Generalmente la lamina continua llena es suministrada continuamente a, y a traves de la configuracion o etapa de retirar de exceso de polvo.6 mm past the end of the other plate (36), the plates being at a 45 ° angle with respect to the continuous sheet, and its vertical height in relation to the continuous sheet being chosen to ensure good contact of the cleaning edge ( 32) of the scraper blade surface cleaner (31) with the continuous sheet while avoiding excessive frictional forces on the continuous sheet. However, it will be evident that many alternative configurations can be conceived. Vacuuming of the dust removed from around the edges (32) of the scraper blade surface cleaner (31) can be conveniently used to ensure that the process continues uniformly and consistently to remove excess dust. The collected dust can be recirculated from the front end of the process for the types of dust that are not degraded or altered by the passage through the process. As can be seen in Figure 1, it may be desirable to use a scraper blade (40) on the bottom surface of the continuous sheet to remove any dust that has been left on the bottom surface of the continuous sheet during processing. Two sheets above the continuous sheet, with one below it located between them, have been found to be particularly satisfactory. Their positions and heights can be chosen in a preferred manner to ensure a good contact of the continuous sheet with each one, while maintaining the curvature or deflection of the continuous sheet in a minimum, to avoid large frictional forces and other forces. Generally the full continuous sheet is continuously supplied to, and through the configuration or step of removing excess dust.
Si se desea y/o fuera necesario, los procesos pueden comprender adicionalmente medios para posteriormente formar hendiduras y/o cortar la lamina continua rellena de polvo a anchuras y/o longitudes deseadas, por ejemplo para proporcionar una cinta. Una cualquiera de una variedad de tales medios se pueden emplear, tal como cuchillos de formacion de hendiduras de cizalla, o cuchillos de formacion de hendiduras de aplastamiento o en particular chichillos de formacion de hendiduras de cizalla giratorios. Se apreciara que tal formacion de hendiduras y/o cortes se puede realizar en la(s) etapa(s) del proceso en lmea despues del llenado, y tfpicamente despues de la retirada del exceso de polvo. Alternativamente, tal formacion de hendiduras y/o corte se puede realizar como una(s) etapa(s) de proceso fuera de la lmea, en donde por ejemplo, la lamina continua llena es almacenada en un rodillo de grandes dimensiones y es transferida a una unidad separada para la formacion de hendiduras y/o cortes. En ambos casos, es deseable que la lamina continua llena sea suministrada de forma continua a, y a traves de, las configuraciones o etapas de formacion de hendiduras y/o corte.If desired and / or necessary, the processes may additionally comprise means for subsequently forming slits and / or cutting the continuous sheet filled with dust to desired widths and / or lengths, for example to provide a tape. Any one of a variety of such means can be employed, such as shear slit formation knives, or crushing slit formation knives or in particular rotating shear slit formation knives. It will be appreciated that such formation of slits and / or cuts can be carried out at the step (s) of the process in line after filling, and typically after removal of excess dust. Alternatively, such slit formation and / or cutting can be performed as a process step (s) outside the line, where for example, the full continuous sheet is stored in a large roll and is transferred to a separate unit for the formation of slits and / or cuts. In both cases, it is desirable that the full continuous sheet be supplied continuously to, and through, the configurations or stages of slit formation and / or cutting.
Preferiblemente, la relacion entre la longitud y la anchura es mayor que 5:1, mas preferiblemente mayor que 10:1 y los mas preferible entre 100:1 y 1000:1. Preferiblemente, los portadores y/o cintas alargados tendran una anchura de aproximadamente 0,5 a 3 cm y mas preferiblemente aproximadamente entre 1 y 2 cm. Las laminas continuas rellenas y/o portadores alargados (por ejemplo, con forma de cinta pueden estar dispuestos enrollados en una bobina o dispuestos en forma de rollo.Preferably, the ratio between length and width is greater than 5: 1, more preferably greater than 10: 1 and most preferably between 100: 1 and 1000: 1. Preferably, the elongated carriers and / or ribbons will have a width of about 0.5 to 3 cm and more preferably about 1 to 2 cm. Continuous filled sheets and / or elongated carriers (for example, in the form of a tape may be arranged wound in a coil or arranged in a roll form.
Los procesos pueden comprender tambien medios para controlar la temperatura ambiente o la humedad relativa del ambiente en el que la aplicacion de polvo tiene lugar. Esto podna ser particularmente relevante cuando son aplicados a la lamina continua polvos sensibles a la humedad. De manera adecuada, el proceso de llenado de lamina continua podna entonces ser realizado en un recinto de temperatura y humedad relativa controladas para adaptarse al material en polvo que esta siendo utilizado. Tal recinto podna estar dimensionado para incluir solo el equipo de suministro y llenado de polvo, siendo la lamina continua suministrada al recinto a traves de una estrecha rendija y fuera a los cuchillos de formacion de hendiduras a traves de otra. Podna demostrar el expediente para encajar el aparato de manejo de aire y filtracion en el recinto, con el fin de proteger a los operarios de la exposicion potencia a cualesquiera polvos daninos. Ademas, se pueden emplear medios para controlar la cara electrostatica presente en la lamina continua o en el polvo. Por ejemplo, un ventilador desionizador, tal como los disponibles de 3M Corporation, puede estar dispuesto para soplar sobre la lamina continua en movimiento antes de que alcance el punto de suministro de polvo.The processes may also comprise means for controlling the ambient temperature or the relative humidity of the environment in which the application of dust takes place. This could be particularly relevant when moisture sensitive powders are applied to the continuous sheet. Suitably, the continuous sheet filling process could then be performed in a controlled temperature and relative humidity enclosure to accommodate the powder material being used. Such an enclosure could be sized to include only the powder supply and filling equipment, the continuous sheet being supplied to the enclosure through a narrow slit and out to the slit formation knives through another. It could demonstrate the file to fit the air handling and filtration apparatus in the enclosure, in order to protect the operators from the exposure to any harmful dust. In addition, means can be used to control the electrostatic face present in the continuous sheet or in the powder. For example, a deionizing fan, such as those available from 3M Corporation, may be arranged to blow on the continuous moving sheet before it reaches the point of powder supply.
Las configuraciones utilizadas para transportar la lamina continua a traves del proceso, junto con la disposicion del rodillo accionado de la etapa de llenado de polvo asf como otros elementos estructurales (por ejemplo, la base maciza y las hojas rascadoras) son elegidos de manera general y de manera adecuada para minimizar la variacion en la tension de la lamina continua a traves de la anchura de la lamina continua. Tambien en el caso en el que en la lamina continua se formen hendiduras en portadores alargados, es deseable controlar la tension de tales portadores de formacion de hendiduras, con el fin de ayudar a mantener una tension uniforme a traves de toda la lamina continua mas aguas arriba, por ejemplo en el punto en el que la lamina continua esta siendo llenada con polvo. Los medios para controlar la tension de la lamina continua son bien conocidos por los expertos en la tecnica. Ademas, el curvado, doblado o arrugamiento que vanan lateralmente, de la lamina continua, asf como la vibracion de borde de lamina continua excesiva se pueden evitar de manera general mediante el uso de configuraciones apropiadas de la trayectoria de lamina continua y el apropiado control de giro de la lamina continua.The configurations used to transport the continuous sheet through the process, together with the arrangement of the driven roller of the powder filling stage as well as other structural elements (for example, the solid base and the scraper blades) are generally chosen and suitably to minimize variation in continuous sheet tension across the width of the continuous sheet. Also in the case where in the continuous sheet grooves are formed in elongated carriers, it is desirable to control the tension of such slit-forming carriers, in order to help maintain a uniform tension across the entire continuous sheet plus water above, for example at the point where the continuous sheet is being filled with dust. The means for controlling the tension of the continuous sheet are well known to those skilled in the art. In addition, the curving, bending or wrinkling that go laterally, of the continuous sheet, as well as the excessive continuous sheet edge vibration can be generally avoided by using appropriate configurations of the continuous sheet path and proper control of continuous blade rotation.
Los polvos finamente divididos generalmente son bien retenidos dentro de las microdepresiones (posiblemente mediante una combinacion de atraccion electrostatica, fuerzas de Van der Waals, atraccion ffsica y, dependiendo de la configuracion de la propia depresion, union o soldadura mecanica) de manera que una capa de cubierta sobre la micriodepresion rellena generalmente no es necesaria para asegurar que el polvo permanece en las microdepresiones. Sin embargo, si se desea y/o es necesario para la proteccion extra del proceso se puede incluir cubrir y/u obturar la superficie de la lamina continua con microdepresiones rellenas de polvo. Esto se puede conseguir fijando un material lamiar adecuado a la superficie de la lamina continua. Adicionalmente oFinely divided powders are generally well retained within microdepressions (possibly by a combination of electrostatic attraction, Van der Waals forces, physical attraction and, depending on the configuration of the depression itself, mechanical bonding or welding) so that a layer Cover on the filled micro-depression is generally not necessary to ensure that the powder remains in the microdepressions. However, if desired and / or necessary for the extra protection of the process, it may include covering and / or sealing the surface of the continuous sheet with powder filled microdepressions. This can be achieved by attaching a suitable laminar material to the surface of the continuous sheet. Additionally or
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
alternativamente, el almacenamiento de la lamina continua o el portador alargado en un estado enrollado afectara a la obturacion de la parte superior de las depresiones a traves del contacto con el lado posterior de la lamina continua o el propio portador alargado en la siguiente vuelta del rollo.alternatively, the storage of the continuous sheet or the elongated carrier in a rolled state will affect the sealing of the upper part of the depressions through contact with the rear side of the continuous sheet or the elongated carrier itself on the next round of the roll .
Los polvos finamente divididos utilizados en los procesos y metodos descritos aqm generalmente tienen un diametro de partfcula de masa media tipicamente de 10 micras o menor. Mas adecuadamente, dicho diametro de masa media es de 7 micras o menor, incluso mas adecuadamente 5 micras o menor, y lo mas adecuado, dicho diametro de masa media esta comprendido entre 1 y 3 micras, con al menos un 90% en masa de partfculas que tienen diametros por debajo de 5 micras.The finely divided powders used in the processes and methods described herein generally have a particle diameter of average mass typically 10 microns or less. More suitably, said average mass diameter is 7 microns or less, even more adequately 5 microns or less, and most suitable, said average mass diameter is between 1 and 3 microns, with at least 90% by mass of particles that have diameters below 5 microns.
Los polvos pueden estar micronizados, por ejemplo, utilizando un molido de energfa de fluido accionado por aire comprimido, tal como el mostrado en “Drug Delivery to the Respiratory Tract” ed. D. Ganderton y T. Jones, publ, Ellis Horwood, Chichester (1987) paginas 89-90, o mediante molidos de etapa repetida o mediante el uso de un sistema de molido de bucle cerrado.The powders may be micronized, for example, using a fluid energy grinding driven by compressed air, such as that shown in "Drug Delivery to the Respiratory Tract" ed. D. Ganderton and T. Jones, publ, Ellis Horwood, Chichester (1987) pages 89-90, or by repeated stage grinding or by using a closed loop grinding system.
Los procesos y metodos descritos aqm, son particularmente adecuados en el llenado de lamina continua y/o la fabricacion de portadores alargados rellenos con sustancias biologicamente activas, tales como medicamentos, agroqmmicos, o productos cosmeticos. Una sustancia biologicamente activa puede, por ejemplo, ser un farmaco, una vitamina o una vacuna. Los polvos utilizados pueden ser una sustancia biologicamente activa en sf misma (por ejemplo partfculas de farmaco micronizadas) o puede ser una sustancia portadora con una sustancia biologicamente activa incorporada en la misma (por ejemplo, mezclas de partfculas de farmaco micronizadas con agentes de volumen de lactosa micronizados u otros excipientes, mezclas de mas de un farmaco micronizado, partfculas revestidas de farmaco seco rociado, o microcapsulas).The processes and methods described herein are particularly suitable in the filling of continuous laminate and / or the manufacture of elongated carriers filled with biologically active substances, such as drugs, agrochemicals, or cosmetic products. A biologically active substance may, for example, be a drug, a vitamin or a vaccine. The powders used may be a biologically active substance in itself (for example micronized drug particles) or it may be a carrier substance with a biologically active substance incorporated therein (for example, mixtures of micronized drug particles with volume agents of micronized lactose or other excipients, mixtures of more than one micronized drug, sprayed dry drug coated particles, or microcapsules).
Ademas, las laminas continuas rellenas y/o los portadores alargados provistos por los procesos y metodos descritos aqm, incluyendo cantidades medidas pequenas bien controladas de una sustancia biologicamente activa se pueden utilizar de manera ventajosa como tales o como parte de sistemas de suministro para la administracion de sustancias en polvo biologicamente activas por via oral (por ejemplo, utilizando un material de lamina continua biodegradable y/o digerible) o por via topica (por ejemplo provisto como parte de una cinta medica o quirurgica, funda, prenda de vestir y/o vendaje) o a traves de suministro transdermial, trasnmucosal (por ejemplo bucal, sublingual) vaginal, rectal, ocular, auditivo para utilizar con seres humanos o animales.In addition, the continuous filled sheets and / or elongated carriers provided by the processes and methods described herein, including small, well-controlled measured amounts of a biologically active substance can be used advantageously as such or as part of delivery systems for administration. of biologically active powder substances orally (for example, using a biodegradable and / or digestible continuous sheet material) or topically (for example provided as part of a medical or surgical tape, sheath, garment and / or bandage) or through transdermial, transnmucosal (eg buccal, sublingual) vaginal, rectal, ocular, auditory delivery for use with humans or animals.
Tales laminas continuas rellenas preparadas y/o portadores alargados son bien adecuados para la aplicacion de cantidades medidas de sustancias en polvo biologicamente activas en el campo de la agricultura, por ejemplo de reguladores de crecimiento, pesticidas, fungicidas u otros productos qmmicos.Such prepared filled continuous sheets and / or elongated carriers are well suited for the application of measured amounts of biologically active powdered substances in the field of agriculture, for example growth regulators, pesticides, fungicides or other chemicals.
Las laminas continuas rellenas o los portadores alargados proporcionados por los procesos descritos aqm son particularmente adecuados para la administracion de medicamentos para inhalacion por un paciente. Las laminas continuas rellenas y/o portadores alargados preferiblemente proporcionaran liberacion constante del medicamento cuando este expuesto a la fuerza utilizada para pulverizar el medicamento. En una realizacion preferida de un dispositivo de aerosol, el medicamento finamente dividido (por ejemplo micronizado) es pulverizado en un estado no aglomerado por el impacto del lado posterior del material laminar. Dispositivos adecuados para pulverizar el medicamento se describen en las Patentes de Estados Unidos N° 5.408.994 y 5.619.984, incorporadas aqm como referencia. Otros dispositivos adecuados que emplean medios distintos al impacto para pulverizar el medicamento a partir de laminas continuas rellenas y/o portadores alargados se describen en la Patente de Estados Unidos N° 5.619.984. La lamina continua rellena y/o el portador alargado tendran preferiblemente forma de cinta que este contenida dentro de un casete y sea hecha avanzar dosis a dosis segun sea requerido por el paciente.Continuous filled sheets or elongated carriers provided by the processes described herein are particularly suitable for administration of medicaments for inhalation by a patient. Continuous filled sheets and / or elongated carriers preferably will provide constant release of the medicament when exposed to the force used to spray the medicament. In a preferred embodiment of an aerosol device, the finely divided medicament (for example micronized) is sprayed in a state not agglomerated by the impact of the back side of the sheet material. Suitable devices for spraying the medicament are described in US Patent Nos. 5,408,994 and 5,619,984, incorporated herein by reference. Other suitable devices that employ non-impact means for spraying the medicament from continuous filled sheets and / or elongated carriers are described in US Patent No. 5,619,984. The filled continuous sheet and / or the elongated carrier will preferably have a tape form that is contained within a cassette and is advanced dose by dose as required by the patient.
Tfpicamente, un area de portador o cinta alargada de 20 mm de longitud y 10 mm de achura por unica dosis es adecuada para utilizar por un inhalador de polvo seco. Tfpicamente, tal area de dosis podna tener 200 a 2000 microdepresiones discretas, cada una de aproximadamente 45 micras de profundidad y aproximadamente 150 micras de diametro. De manera ventajosa, las filas de microdepresiones a lo largo del eje longitudinal del portador o la cinta alargados no se situan exactamente paralelos al eje, sino que en su lugar se situan sesgados en un pequeno angulo (por ejemplo 0,5° a 2°) con el, con el fin de evitar los “efectos de quantizacion” causados por la variabilidad lateral en las posiciones de formacion de hendiduras. (El angulo de sesgo se puede elegir apropiado a la distancia de separacion de las microdepresiones y a la anchura de formacion de hendiduras deseada, de manera que un volumen de microdepresion total esta presente en cada area de dosis (por ejemplo 20 mm x 10 mm), sin importar en donde se produzca la formacion de hendiduras, lateralmente). Para utilizar en inhaladores de polvo seco, preferiblemente, las microdepresiones estan dispuestas mediante el grabado en relieve por fusion de una capa de polietileno de baja densidad (LDPE) utilizando un rodillo de patron fotolitografico y de grabado o mecanizando con diamantare. De manera adecuada, la capa de LDPE anteriormente mencionada esta dispuesta en un raspado de papel o un respaldo estratificado de papel/LDPE (con el papel entre las dos capas de LDPE).Typically, an area of carrier or elongated tape 20 mm in length and 10 mm in achura for a single dose is suitable for use by a dry powder inhaler. Typically, such a dose area could be 200 to 2000 discrete microdepressions, each about 45 microns deep and about 150 microns in diameter. Advantageously, the rows of microdepressions along the longitudinal axis of the elongated carrier or tape are not positioned exactly parallel to the axis, but instead are positioned skewed at a small angle (for example 0.5 ° to 2 ° ) with it, in order to avoid the "quantization effects" caused by lateral variability in the slit formation positions. (The angle of bias can be chosen appropriate to the separation distance of the microdepressions and to the desired slit formation width, so that a total microdepression volume is present in each dose area (for example 20 mm x 10 mm) , regardless of where the slit formation occurs, laterally). For use in dry powder inhalers, preferably, the microdepressions are arranged by embossing by fusion of a layer of low density polyethylene (LDPE) using a roller of photolithographic pattern and engraving or machining with diamantare. Suitably, the aforementioned LDPE layer is arranged in a paper scrape or a laminated paper / LDPE backing (with the paper between the two layers of LDPE).
Para la administracion por inhalacion, tales medicamentos incluyen cualquier farmaco o combinacion de farmacos que se puedan administrar por inhalacion, esto es, un solido o que puedan ser incorporados en un portador solido. Los farmacos adecuados incluyen aquellos para el tratamiento de desordenes respiratorios, por ejemplo, broncodilatadores, corticosteriodes, y farmacos para la profilaxis de asma. Otros farmacos como agentesFor administration by inhalation, such medications include any drug or combination of drugs that can be administered by inhalation, that is, a solid or that can be incorporated into a solid carrier. Suitable drugs include those for the treatment of respiratory disorders, for example, bronchodilators, corticosteroids, and drugs for asthma prophylaxis. Other drugs as agents
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
anorecticos, anti-depresivos, anti-hipertensos, agentes anti-neoplasticos, agentes anti-colinergicos, agentes dopaminergicos, analgesicos narcoticos, agentes de bloqueo beta-adrenergicos, prostaglandinas,anorectic, anti-depressant, anti-hypertensive, anti-neoplastic agents, anti-cholinergic agents, dopaminergic agents, narcotic analgesics, beta-adrenergic blocking agents, prostaglandins,
simpaticomimeticos, tranquilizantes esteroides, vitaminas, y hormonas sexuales se pueden emplear para la administracion por inhalacion. Se pueden emplear de manera similar, antianginatos, antibacteriales, antibioticos, antiinflamatorios, farmacos anti-migrana, anti-peptidos, antivirales, farmacos cardiovasculares, hipoglucemicos, inmunomoduladores, surfactantes pulmonares, y vacunas.Sympathomimetics, steroid tranquilizers, vitamins, and sex hormones can be used for administration by inhalation. Similarly, anti-alginates, antibacterials, antibiotics, anti-inflammatories, anti-migraine drugs, anti-peptides, antiviral drugs, cardiovascular drugs, hypoglycemic drugs, immunomodulators, pulmonary surfactants, and vaccines can be used.
Se prefiere para el suministro por inhalacion que el medicamento empleado presente una potencia que permita que sea cargada una unica dosis en la lamina continua y/o el portador alargado en un area de menos de aproximadamente 25 cm2 y preferiblemente menos de aproximadamente 5 cm2. Mas preferida es una lamina continua y/o portador alargado que contiene un farmaco de tal manera y de tal tipo que entre 0,25 y 2,5 cm2, lo mas preferible entre 1,5 y 2,25 cm2, de lamina continua y/o portador alargado contendran una unica dosis cuando se utilice en un dispositivo tal como el descrito en la patente de Estados Unidos N° 5.408.994 o 5.619.984. Mencionado diferencialmente, dado que una lamina continua y/o portador alargado relleno pueden convenientemente llevar entre aproximadamente 25 y 500 |jg de polvo por cm2, la potencia del medicamento preferiblemente sera tal que una unica dosis puede ser llevada en los anteriormente expuestos 0,25 a 2,5 cm2 de lamina continua y/o portador alargado.It is preferred for inhalation delivery that the medicament used has a potency that allows a single dose to be charged on the continuous sheet and / or the elongated carrier in an area of less than about 25 cm2 and preferably less than about 5 cm2. More preferred is a continuous sheet and / or elongated carrier that contains a drug in such a way and such that between 0.25 and 2.5 cm2, most preferably between 1.5 and 2.25 cm2, of continuous sheet and / or elongated carrier will contain a single dose when used in a device such as that described in US Patent No. 5,408,994 or 5,619,984. Differentially mentioned, since a continuous laminate and / or elongated carrier filled can conveniently carry between about 25 and 500 µg of powder per cm2, the potency of the medicament will preferably be such that a single dose can be carried in the above exposed 0.25 2.5 cm2 of continuous sheet and / or elongated carrier.
Farmacos a modo de ejemplo que se pueden emplear para el suministro por inhalacion incluyen pero no se limitan a: albuterol, terbutalina, fenoterol, metaproterenol, isoproterenol, isoetardina, bitolterol, epinefrina, tulobuterol, bambuterol, reproterol, adrenalina, ipratropio, oxitropia, tiotropio, beclometasona, betametasona, flunisolido, budesonida, mometasona, ciclesonida, rofleponida, aminofilina, difilina, teofilina, cromolin sodico, nedocromil sodico, ketotifeno, azelastina, ergotamina, ciclosporina, salmeterol, fluticasona, formoterol, procaterol, indacaterol, TA2005, omalizumab, montelukast, zarfilukast, fosfato de sodio betametasona, dexametasona, fosfato sodico de dexametasona, acetato de dexametasona, prednisona, acetato de metilprednisolona, zoleuton, insulina, atropina, prednisolona, benzfetamina, clorfentermina, amitriptilina, imiprapina, clonidina, antinomicina c, bromocriptina, buprenorfina, pentamidina, calcitonina, leuprolida, alfa-1-antitripsina, interferones, propranolol, lacicortona, triamcinolona, dinoprost, xilometazolina, diazepam, lorazepam, acido folico, nicotinamida, clenbuterol, etinilestradiol, levonorgestrel, y sales farmaceuticamente aceptables o esteres de las mismas tales como sulfato de albuterol, fumarato de formoterol, hidroxinafroato de salmeterol, dipropionato de beclometasona, acetonida de triamcinolona, propionato de fluticasona, bromuro de tiotropio, acetado de leuprolide y furoato de mometasona.Exemplary drugs that can be used for inhalation delivery include but are not limited to: albuterol, terbutaline, fenoterol, metaproterenol, isoproterenol, isoetardin, bitolterol, epinephrine, tulobuterol, bambuterol, reproterol, adrenaline, ipratropium, oxytropia, tiotropium , beclomethasone, betamethasone, flunisolide, budesonide, mometasone, ciclesonide, rofleponide, aminophylline, diphilin, theophylline, sodium chromolin, nedocromil sodium, ketotifen, azelastin, ergotamine, cyclosporine, salmeterol, fluticacaterol, acetaminalcaterolone, prokalcaterolonea, monolitholterolone, acetaminalcaterolone, albuminase, testosterone , zarfilukast, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, prednisone, methylprednisolone acetate, zoleuton, insulin, atropine, prednisolone, benzfetamine, chlorphentermine, amitriptyline, imidrapin, bipreptin, bipreptin, bipreptin, bipretin pentamidine, calcitonin, leuprolide, alpha-1-antitrypsin, interferons, propra nolol, lacicortone, triamcinolone, dinoprost, xylometazoline, diazepam, lorazepam, folic acid, nicotinamide, clenbuterol, ethynyl estradiol, levonorgestrel, and pharmaceutically acceptable salts or esters thereof such as albuterol sulfate, formoterol hydrochloride diphlorate, formoterol hydrochloride Beclomethasone, triamcinolone acetonide, fluticasone propionate, tiotropium bromide, leuprolide acetate and mometasone furoate.
Mas farmacos que pueden tambien ser suministrados por inhalacion incluyen pero no se limitan a aspirina, acetaminofen, ibuporfeno, naproxen sodico, hidrocloruro de buprenorfina, hibrocloruro de propoxifeno, napsilato de propoxifeno, hidrocloruro de meperidina, hidrocloruro de hidromorfona, sulfato de morfina, citrato de fentanilo, hidrocloruro de oxicodona, forfato de coderna, bitartrato de dihidrocodeina, hidrocloruro de pentazocina, bitartrato de hidrocodona, tartrato de levorfanol, diflunisal, diamorfina, salicilato de trolamina, hidrocloruro de metadona, hidrocloruro de nalbufina, nalorfina, tetrahidrocannabinol, acido mefenamico, tartrato de butorfanol, salicicato de colina, butalbital, citrato de feniltoloxamina, citrato de difenidramina, hidrocloruro de cinamedrina, meprobamato, tartrato de ergotamina, hidrocloruro de propanolol, mucato de isometepteno, dicloralfenazona, sumatriptan, rizatriptan, zolmitriptan, zolmitriptan, naratriptan, eletriptan, barbituratos (por ejemplo, pentobarbital, pentobarbital sodico, secobarbital sodico), benzodiazapinas (por ejemplo, hicrocloruro de flurazepam, triazolam, tomazeparm, hidrocloruro de midazilam, lorazepam, hidrocloruro de buspirona, prazepam, hidrocloruro de clordiazepoxido, oxazepam, dipotasio de clorazepato, diazepam, temazepam), lidocarna, prilocarna, xilicama, bloqueadorees beta- adrenergicos, bloqueadores de cala de calcio (por ejemplo, nifedipina, hidrocloruro de diltiazem, y similares) nitratos (por ejemplo, nitroglicerina, dinitrato de isosorbida, tetranitrato de pentaeritritol, tetranitrato de eritritil), pamoato de hidroxicina, hidrocloruro de hidroxicina, alprazolam, droperidol, halazepam, clormezanona, haloperidol, succinato de loxapina, hidrocloruro de loxapina, tioridazina, hidrocloruro de tioridazina, tiotiexeno, hidrocloruro de flufenazina, decanoato de flufenazina, enantato de flufenazina, hidrocloruro de triofluoperazina, hidrocloruro de clorpromazina, perfenazina, citrato de litio, proclorperazina, carbonato de litio, tosilato de bretilio, hidrocloruro de esmobol, hidrocloruro de varapamil, amiodaradona, hidrocloruro de encainida, digoxin, digitoxin, hidrocloruro de mexiletina, forfato de disopyramida, hidrocloruro de procainamida, sulfato de quinidina, gluconato de quinidina, poligalacturonato de quinidina, acetato de flecainida, hidrocloruro de tocainida, hidrocloruro de lidocaina, penilbutazona, sulindac, penicilamina, salsalato, piroxicam, azatioprina, idometacina, meclofenamato de sodio, tiomalato sodico de oro, ketoprofen, auranofina, aurotioglucosa, tolmetin sodico, colchicina, alopurinol, heparina, heparina sodica, warfarina sodica, urokinasa, estreptoquinasa, altoplasa, acido aminocaproico, pentoxifilina, empirina, ascriptin, acico valproico, divalproato sodico, fenitoina, fenitoina sodica, clonazepam, primidona, fenobarbitol, fenobarbitol sodico, carbamazepina, amobarbital sodico, metsuximida, metarbital, mefobarbital, mefenitoina, fensuximida, parametadiona, etotoina, fenacemida, secobarbitol sodico, clorazepato de dipotasio, trimetadiona, etosuximida, hidrocloruro de doxepina, amoxapina, hidrocloruro de trazodona, hidrocloruro de amitriptilina, hidrocloruro de maprotilina, sulfato de fenelzina, hidrocloruro de desepramina, hidrocloruro de nortiptilina, sulfato de tranilcipromina, hidrocloruro de fluoxetina, hidrocloruro de doxepina, hidrocloruro de imipramina, pamoato de imipramina, nortriptilina, hidrocloruro de amitriptilina, isocarbozacida, hidrocloruro de desipramina, maleato de trimipramina, hidrocloruro de protriptilina, hidrocloruro de hidroxizina, hidrocloruro de difenhidramina, maleato de clorfenhidramina, maleato de bromfenhidramina, clemastina, azelastina, hidrocloruro de ciproheptadina, citrato de terfenadina, clemastina, hidrocloruro de triprolidina, maleato de carbinoxamina, hidrocloruro de difenilpiralina, tartrato de fenindamina, lamivudina, abacavir, aciclovir, ganciclovir, valganciclovir, cidofovir, forcarnet, maleato de azatadina, hidrocloruro deMore drugs that can also be supplied by inhalation include but are not limited to aspirin, acetaminophen, ibuporphene, sodium naproxen, buprenorphine hydrochloride, propoxyphene hydrochloride, propoxyphene napsilate, meperidine hydrochloride, hydrochloride hydrochloride citrate hydroforphine fentanyl, oxycodone hydrochloride, coderna formate, dihydrocodeine bitartrate, pentazocine hydrochloride, hydrocodone bitartrate, levorphanol tartrate, diflunisal, diamorphine, trolamine salicylate, methadone hydrochloride, methamphenochloride methanochloride butorphanol, salicicato choline, butalbital, phenyltoloxamine citrate, citrate diphenhydramine hydrochloride, cinnamedrine, meprobamate, ergotamine tartrate, propanolol hydrochloride, isometheptene mucate, dichloralphenazone, sumatriptan, rizatriptan, zolmitriptan, zolmitriptan, naratriptan, eletriptan, barbiturates (for example, pen tobarbital, sodium pentobarbital, secobarbital sodium), benzodiazapine (for example, flurazepam hydrochloride, triazolam, tomazeparm, midazilam hydrochloride, lorazepam, buspirone hydrochloride, prazepam, hydrochloride, oxordiapapopazezene dialozepazoeamide, cloazepazepazoeamideamide, cloazepazeze diazepaepazoleamide, chlorazepazepazoeamideamide, clovazepazepazoeamideamide, chlorazepazepazoamideamide, chlorazepazepazoleamide, chlorazepazepazoleamide, chlorapazepazoleamide, chlorazepazepazoleamide, chlorazepazepazoleamide, chlorazepazepazoleamide, chlorazepazezozoazoleamideamide, chlorazepazepoxyl diazepazoleamideamide , prilocarna, xilicama, beta-adrenergic blockers, calcium cove blockers (for example, nifedipine, diltiazem hydrochloride, and the like) nitrates (for example, nitroglycerin, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate) hydroxyzine, hydroxyzine hydrochloride, alprazolam, droperidol, halazepam, clormezanone, haloperidol, loxapine succinate, loxapine hydrochloride, thioridazine, thioridazine hydrochloride, thiothiexenne, fluphenazine hydrochloride, fluoroazethazethanorazacenorazine, fluoroazethazethanorazine, fluoroazethazine oxychloroacetoleazethane, fluoroazethazethanorazine, fluoroazethazethanorazine, hydrofluorophazethanorazachlorine, oxychlorine chlorpromazine, perphenazine, lithium citrate, prochlorperazine , lithium carbonate, bretilium tosylate, esmobol hydrochloride, varapamil hydrochloride, amiodaradone, encainide hydrochloride, digoxin, digitoxin, mexyletin hydrochloride, disopyramide formate, procainamide hydrochloride, quinidine polycinidine, quinidine glucine , flecainide acetate, tocainide hydrochloride, lidocaine hydrochloride, penilbutazone, sulindac, penicillamine, salsalate, piroxicam, azathioprine, idomethacin, sodium meclofenamate, golden sodium thiomalate, ketoprofen, auranofin, aurothinopulin, sodictin-threopygine , sodium heparin, warfarin sodium, urokinase, streptokinase, altoplase, aminocaproic acid, pentoxifylline, empirin, ascriptin, valproic acid, sodium divalproate, phenytoin, sodium phenytoin, clonazepam, primidone, phenobarbitol, phenobarbitol, sodium methobarbitol, sodium methobarbitol, sodium , mefobarbital, mefenitoina, fensuximida, parametadiona, etotoina , Phenacemide, secobarbitol sodium, clorazepate dipotassium, trimethadione, ethosuximide, doxepin hydrochloride, amoxapine, trazodone hydrochloride, amitriptyline hydrochloride, maprotiline hydrochloride, phenelzine sulfate, hydrochloride desepramina hydrochloride, nortriptyline, tranylcypromine sulfate, hydrochloride fluoxetine, doxepine hydrochloride, imipramine hydrochloride, imipramine pamoate, nortriptyline, amitriptyline hydrochloride, isocarbozazide, desipramine hydrochloride, trimipramine maleate, protriptyline hydrochloride, hydroxychlorine malehydrochlorine hydrochloride hydrochloride clemastine, azelastine, cyproheptadine hydrochloride, terfenadine citrate, clemastine, triprolidine hydrochloride, carbinoxamine maleate, diphenyl spiraline hydrochloride, phenylamine tartrate, lamivudine, abacavir, acyclovir, ganciclovir, valgancvirate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, valgancrylate, atridolate, valgancrylate, valgancrylate, valgancrylate, atriatin, fordichlorohydrate na, hydrochloride
55
1010
15fifteen
20twenty
2525
3030
tripelenamina, maleato de dexclorfeniramina, hidrocloruro de metdizalina, tartrato de trimprazina, camsilato de trimetafan, hidrocloruro de fenoxibenzamina, hidrocloruro de pargilina, deserpidina, diazoxida, monosulfato de guanetidina, minoxidil, rescinamina, nitroprusida sodica, rauwolfia serpentina, alseroxilon, melisato de fentolamina, reserpina, calcitonina, hormona paratiroide, acitretina, sulfato de amikacin, aztreonam, benzidamina, calcipotriol, cloramfenicol, palmitato de cloramfenicol, succinato sodico de cloramfenicol, hidrocloruro de ciproflozacin, palmitato de clindamicina, fosfato de clindamicina, efalizumab, metronidazola, hidrocloruro de metronidazola, sulfato de gentamicina, hidrocloruro de lincomicina, sulfato de tobramicina, tacrolimus, hidrocloruro de vancomicina, sulfato de polimixina B, colistimetato sodico, sulfato de colistin, tetraciclina, griseofulvin, keloconazol, interferon gamma, zidovudina, hidrocloruro de amantadina, ribavirina, aciclovir, pentamidina, por ejemplo isoetionato de pentamidina, cefalosporinas (por ejmeplo, cefazolina sodica, cefradina, cefaclor, cefapirina sodica, ceftizoxima sodica, cefoperazona sodica, cefotetan disodico, axotil cefutoxima, cefotaxima sodica, monohidrato de cefadroxil, ceftazidima, cefalexin, cefalotin sodico, monohidrato de hidrocloruro de cefalexina, naftato de cefamandol, cefoxitina sodica, cefonicida sodica, ceforanida, ceftriaxona sodica, ceftazidima, cefacroxil, cefradina, cefuroxima sodica y similares), penicilinas (por ejemplo, ampicilina, amoxicilina, penicilina G benzatina, civlacilina, ampicilina sodica, menicilina G potasica, penicilina V potasica, piperacilina sodica, oxacilina sodica, hidrocloruro de bacampicilina, cloxacilina sodica, ticarcilina disodica, azlocilina sodica, carbecilina indanil sodica, penicilona G potasica, penicilina G procaina, meticilina sodica, nafcilina sodica, y similares), eritromicinas (por ejemplo, etilsuccinato de eritromicina, estolato de eritromicina, lactobionato de aritromicina, siearato de eritromicina, etilsuccinato de eritromicina, y similares), tetraciclinas (por ejemplo, hidrocloruro de tetraciclina, hiclato de doxiciclina, hidrocloruro de minociclina, GM-CSF, efedrina, pseudoefedrina, cloruro de amonio, androgenos (por ejemplo, danazol, cipionato de testosterona, fluoximesterona, etiltostosterona, enanihato de metiltestosterona, fluoximesterona, cipionato de testosterona), estrogenos (por ejemplo, estradiol, estropipato, estrogenos conjugados), progestinas (por ejemplo, acetato de metoxiprogesterona, acetato de noretindrona), levotiroxina sodica, insulina humada, insulina de vaca purificada, insulina de cardo purificada, gliburida, clorpropamida, glipizida, tolbutamida, tolazamida, rosiglitazona, pioglitazona, troglitazona, clofibrato, dextrotiroxina sodica, probucol, lovastatin, rosuvastatin, niacin, DNase, anginasa, superoxido dismutasa, lipasa, calcitonion, alfa-1-antitripsina, interferonas, acido nucleicos sentido o anti-sentido que codifican cualquier protema adecuados para el suministro por inhalacion, eritropoietina, famotidina, cimatidina, hidrocloruro de ranitidina, omeprazol, esomeprazol, lanzoprazol, hidrocloruro de meclizina, nabilona, proclorperazina, dimenhidrinato, hidrocloruro de prometazina, tietilperazina, scopolamina, sildenafil, vardenafil, cilomilast, imiquimod o resiquimod. Cuando sea apropiado, estos farmacos se pueden suministrar en forma de sales alternativas.tripelenamine, dexchlorpheniramine maleate, metdizaline hydrochloride, trimprazine tartrate, trimetafan camsylate, phenoxybenzamine hydrochloride, pargiline hydrochloride, deserpidine, diazoxide, guanetidine monosulfate, minoxidro, nitroprisamine, albuminase, phenolamine, albuminase reserpine, calcitonin, parathyroid hormone, acitretin, amikacin sulfate, aztreonam, benzidamine, calcipotriol, chloramphenicol, chloramphenicol palmitate, chloramphenicol sodium succinate, ciproflozacin hydrochloride, clindamycin palmitate, clindamycin hydrochloride, methylatronzole phosphate gentamicin sulfate, lincomycin hydrochloride, tobramycin sulfate, tacrolimus, vancomycin hydrochloride, polymyxin B sulfate, sodium colistimethate, colistin sulfate, tetracycline, griseofulvin, keloconazole, interferon gamma, zidovudine, hydrochloride acrylamide , by Isethionate example pentamidine, cephalosporins accessories (eg, cefazolin sodium, cephradine, cefaclor, cephapirin sodium, liothyronine sodium ceftizoxime, cefoperazone sodium, cefotetan disodium, axotil cefutoxime, cefotaxime, cefadroxil monohydrate, ceftazidime, cephalexin, sodium cephalotin, hydrochloride monohydrate cephalexin, cephamandol naphtate, cefoxitin sodium, cefonicide sodium, ceforanide, ceftriaxone sodium, ceftazidime, cefacroxil, cefradine, cefuroxime sodium and the like), penicillins (for example, ampicillin, amoxicillin, penicillin G benzinic ampicilla, malecinic ginazin, potassium benzathic acid, malecinic ampulin, ginazinic potassium, sodinic acid, malecinic acid , penicillin V potassium, piperacillin sodium, oxacillin sodium, bacampicillin hydrochloride, cloxacillin sodium, disodium ticarcillin, azlocillin sodium, carbecillin indanyl sodium, penicillone G potassium, penicillin G procaine, methicillin sodium, similar naphcillin, example naphcillin, naphthromine , erythromycin ethyl succinate, erythromycin stolate, lactobion Arythromycin aether, erythromycin siearate, erythromycin ethyl succinate, and the like), tetracyclines (e.g., tetracycline hydrochloride, doxycycline hyclate, minocycline hydrochloride, GM-CSF, ephedrine, pseudoephedrine, ammonium chloride, example Danazol, testosterone cypionate, fluoxymesterone, ethyl tostosterone, methyltestosterone enanihate, fluoxymesterone, testosterone cypionate), estrogens (for example, estradiol, stropipate, conjugated estrogens), progestins (for example, methoxyprogesterone acetate, norethindin acetate) , humada insulin, purified beef insulin purified thistle, glyburide, chlorpropamide, glipizide, tolbutamide, tolazamide, rosiglitazone, pioglitazone, troglitazone, clofibrate, SODIUM dextrothyroxine, probucol, lovastatin, rosuvastatin, niacin, DNase, anginasa, superoxide dismutase, lipase, calcitonion, alpha-1-antitrypsin, interferons, sense nucleic acid or anti-sense encoding any protein suitable for delivery by inhalation, erythropoietin, famotidine, cimatidine, ranitidine hydrochloride, omeprazole, esomeprazole, lanzoprazole, meclizine hydrochloride, nabilone, prochlorperazine, dimenhydrinate, hydrochloride of promtazinazine, velpentazine, cylethazine, cyclostromedinine, cyclostromedin, cyclostromedin, cyclostromedin, cyclostromedinine , imiquimod or resiquimod. When appropriate, these drugs can be supplied in the form of alternative salts.
El medicamento puede comprender uno o mas farmacos, que tengan una o mas formas de partfcula, o pueden incluir uno o mas excipientes fisiologicamente aceptables o inertes.The medicament may comprise one or more drugs, which have one or more particle forms, or may include one or more physiologically acceptable or inert excipients.
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2006005723 | 2006-03-23 | ||
GB0605723 | 2006-03-23 | ||
PCT/US2007/064654 WO2007112267A2 (en) | 2006-03-23 | 2007-03-22 | Powder filling processes |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2586429T3 true ES2586429T3 (en) | 2016-10-14 |
Family
ID=57100833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07759133.7T Active ES2586429T3 (en) | 2006-03-23 | 2007-03-22 | Powder filling process |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2586429T3 (en) |
-
2007
- 2007-03-22 ES ES07759133.7T patent/ES2586429T3/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210162146A1 (en) | Powder filling processes | |
US20210178089A1 (en) | Dry powder inhaler dose counters | |
ES2582560T3 (en) | Powder supply apparatus | |
ES2337350T3 (en) | DRY POWDER INHALER FOR USE WITH DISPENSING MEDIA ACTIVATED BY PIEZOELECTRIC POLYMERS AND ASSOCIATED BLISTERS CONTAINERS THAT INCLUDES A PIEZOELECTRIC POLYMER MATERIAL. | |
ES2650862T3 (en) | Dry powder inhalers | |
US20040025877A1 (en) | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages | |
BRPI0710604A2 (en) | variable dosage inhalation device | |
BR112014008601B1 (en) | METHOD OF MANUFACTURING AEROSOL TUBES FOR MEDICAL SUPPLIES | |
JP2007530671A (en) | Dry powder formulation for pre-weighed DPI | |
ES2586429T3 (en) | Powder filling process |